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Summary 
This thesis describes the use of phage display for the isolation of autoantigens in 
rheumatoid arthritis. The potential of the technology is demonstrated by the isolation of 
an autoantigen, eukaryotic translation elongation factor 1a1 (eEF 1 (x 1) from a fibroblast 
cDNA library using rounds of selective enrichment with IgG from RA patients. 
Subsequently in order to isolate joint-specific antigens a phage-displayed cDNA library 
from rheumatoid pannus was generated and screened with analogous procedures. From 
the clones isolated, putative candidate autoantigens were identified. The presence of anti- 
eEF 1a1 autoantibodies in approximately 20% of patients with RA was confirmed and 
extended in larger panels of sera, and the finding of anti-eEF la1 shown to be relatively 
specific for RA. In contrast autoantibodies to the activation-induced negative regulator 
of T cells, CTLA-4 were not found in contrast to a previous report. The relevance of 
these findings for the use of antibodies in the diagnosis and prediction of disease 
characteristics in RA are discussed. 
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1 Introduction 
1.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a systemic disease whose characteristic clinical features 
include a symmetrical polyarthropathy affecting large and small joints often leading to 
progressive joint destruction. The prevalence in Europe and North America is 
approximately I% (Sangha, 2000) with a female to male predominance of around 3: 1 and 
it is therefore a leading cause of disability in these populations. Considerable 
heterogeneity exists at the clinical level in terms of mode of onset, pattern of joint 
involvement, severity, extra-articular features and response to treatment suggesting that 
the term rheumatoid arthritis includes individuals with a spectrum of pathological states 
all leading to persistent synovial inflammation (Weyand et al., 1998b). Etiopathogenesis 
is believed to be multifactorial with genetic and environmental factors playing a part in 
susceptibility and severity. 
1.2 The influence of genetic factors in susceptibility to RA 
Twin and family studies suggest that genetic factors account for a substantial proportion, 
perhaps 30-50% of the susceptibility to RA (Barton and Ollier, 2002), (Deighton et al., 
1992). This risk can be conveniently expressed as Xs, the coefficient of familial 
clustering and is calculated as the ratio of disease prevalence of siblings of probands to 
the population prevalence. Values for %s of 5-10 have been estimated for RA (Oilier and 
Worthington, 1997). Estimating ks for each locus can assess the contribution of 
individual loci to the overall genetic susceptibility. The association of RA with the 
serologically defined HLA DR4 was first described more than twenty years ago (Stastny, 
1978) and this association has been confirmed in a number of studies although is variable 
in different ethnic groups. The Xs value for this association has been estimated as 1.8 
(Marlow et al., 1997) suggesting that HLA DR4 accounts for around one-third of the 
genetic component of susceptibility. Although this is the major genetic association with 
susceptibility to RA two-thirds remains unaccounted for and therefore other loci are 
likely to play a role. A number of approaches including genome wide screening, case- 
control association studies and family based transmission-disequilibrium testing of 
candidate genes are currently being employed to search for other disease-associated loci 
(Barton and Oilier, 2002). 
1.3 Pathological changes in RA synovial membrane 
Early histological changes in RA synovial membrane include hyperplasia of the intimal 
lining layer fibroblast-like synoviocytes and macrophages, neoangiogenesis, and the 
accumulation of a cellular infiltrate in the sublining layer comprising T and B cells, 
plasma cells, macrophages, dendritic cells, NK cells, mast cells and neutrophils (Tak and 
Breedveld, 1999). The advent of needle arthroscopy has allowed the description of 
macroscopic features of synovial inflammation that include macroscopic neoangiogenesis 
and the formation of villi (Reece et al., 1999). Microscopically three distinct patterns of 
cellular organization recognised as diffuse, follicular and granulomatous synovitis have 
been described and appear to correlate with particular cytokine profiles suggesting that 
each may represent a subgroup of patients with distinct pathogenetic mechanisms 
(Klimiuk et al., 1997). Later changes include the development of fibrosis and the 
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destruction of bone and cartilage. This invasive and destructive infiltrate is often referred 
to as `pannus'. 
1.4 Pathogenic mechanisms in RA 
The majority of cells in the intimal and sublining layers are macrophages and activated 
fibroblasts (Tak and Breedveld, 1999) and are believed to play a major effector role. 
These cell types show a highly activated phenotype and secrete a number of soluble 
mediators such as cytokines and matrix metalloproteinases resulting in persistent 
inflammation and joint damage (Choy and Panayi, 2001). The importance of 
macrophage-derived mediators such as TNFa is illustrated by the efficacy of anti-TNFa 
therapy in patients with RA (Lipsky et al., 2000; Maini et al., 1999). Much less clear is 
the nature of the upstream events that drive the recruitment, proliferation and 
maintenance of these cells in the synovium. Close spatial arrangements of CD4+ T cells, 
B cells and dendritic cells amounting to germinal centre-like structures in some cases 
(Klimiuk et al., 1997) suggests that chronic activation may be occurring, however 
synovial T cells do not express classical markers of activation such as the IL-2 receptor, 
nor secrete IL-2 and IFNy indicating they are in an unusual state of differentiation (see 
below). 
1.5 HLA association with RA - the shared epitope hypothesis 
Understanding of the molecular basis of the association of particular HLA DR types with 
RA was significantly advanced in the late 1980s when sequence analysis of disease 
associated HLA DR molecules from different populations revealed a common amino acid 
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Table 1. RA associated DRß alleles - the shared epitope. 
DRß chain residue 
57 67 70 71 74 86 
RA associated alleles 
DRB1*0101 D L Q R A G 
DRB1*0102 D L Q R A V 
DRB1*0104 D L Q R A V 
DRB 1 *0401 D L Q K A G 
DRB 1 *0404 D L Q R A V 
DRB 1 *0405 S L Q R A V 
DRB 1 *0408 D L Q R A G 
DRB 1 *0409 S L Q K A G 
DRB1*0410 S L Q R A V 
DRB1*0413 D L Q K A V 
DRB1*0416 D L Q K A G 
DRB1*0419 D L Q R A G 
DRB 1 *0421 D L Q K A G 
DRB1*1402 D L Q R A G 
DRB1*1406 D L Q R A V 
DRB1*1001 D L Q R A G 
RA non-associated alleles 
DRB1*0103 D I D E A G 
DRB 1 *0402 D I D E A V 
DRB 1 *0403 D L Q E A V 
DRB 1 *0406 D L Q E A V 
DRB 1 *0407 D L Q E A G 
DRB1*0411 S L Q E A V 
DRB1*0412 S D Q L A V 
DRB1*0414 D D Q R A G 
DRB1*0415 D D Q R A V 
DRB 1 *0417 S L Q E A G 
DRB1*0418 D D Q L A V 
DRB1*0420 D L Q E A G 
DRB 1 *0422 D L Q G A V 
DRB1*1401 A R Q E A V 
DRB 1 *0901 V R Q E A V 
Table 1. Sequence comparison of RA-associated and non-associated DRB 1 alleles in the third 
hypervariable region. Residues in bold represent those believed to be critical for peptide binding. 
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motif in the DRß chain referred to as the "shared epitope" (table 1) (Gregersen et al., 
1987). Importantly different DRB 1 alleles appear to influence the severity of disease as 
well as susceptibility with homozygosity for DRB*0401 associated with the most severe 
phenotype and particularly extra-articular disease (Weyand et al., 1995). A number of 
structural and functional studies have demonstrated that residues 70,71 and 74 form part 
of an alpha helix of the DR(3 chain that is critical in determining the peptide binding 
specificity of each DR molecule (Wucherpfennig and Strominger, 1995). Disease- 
associated alleles encode a positively charged residue at position 71 (K or R) and hence 
accommodate peptides with a negatively charged residue at position 4 (P4) of a putative 9 
amino-acid peptide bound in the groove of the encoded 0 chain. The pemphigus 
vulgaris-associated and RA non-associated DRB 1 *0402 allele differs from DRB 1 *0401 
and 0404 only by carrying a negatively charged residue at position (371, therefore 
accomodating peptides with a positive charge at position P4 (Hammer et al., 1995) (table 
1). Such studies have provided strong though indirect evidence that the HLA association 
with RA is due to a functional effect of the associated alleles and not related to a linked 
susceptibility locus. 
The only known function of MHC class II molecules is the presentation of peptide 
antigen to T cells, supporting the view that specific T cell/MHC class II/peptide 
interactions are important in the pathogenesis of RA. A number of mechanisms have 
been proposed to explain how such interactions could directly influence susceptibility 
(Buckner and Nepom, 2002), all fall into one of two broad categories - the presentation 
of unique peptide antigens to T cells, or in shaping of the T cell repertoire during thymic 
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selection. Studies of animal models as well as analysis of T and B cell responses of 
patients with RA have contributed to attempts to understand the influence of the shared 
epitope on disease susceptibility. 
1.6 Evaluating the shared epitope hypothesis in vivo. 
That the shared epitope hypothesis is a biological plausibility is supported by 
considerable evidence, the majority from studies of experimental models. Three such 
systems are discussed below. 
1.6.1 Collagen-Induced Arthritis (CIA) -a disease dependent on specific T cells and 
antibody directed against a component of articular cartilage. 
Type II collagen is specific to diarthrodial joints. Immunisation of susceptible strains of 
rodents with heterologous type II collagen results in a severe polyarticular arthritis 
(Trentham et al., 1977). Onset usually occurs around day 28 following the initial 
immunisation and the disease follows a monophasic course with synovitis, erosions of 
bone and cartilage and eventual healing by fibrosis and ankylosis (Stuart et al., 1985). 
Complement fixation by CII-specific antibody has been clearly shown to be the 
mechanism of pathology (Watson et al., 1987). Using a large panel of congenic B 10 
mouse strains susceptibility to CIA induced with chick CII was shown to be associated 
with the MHC class II isotype H-2q (Wooley et al., 1981) and accompanied by strong 
antigen-specific T cell and autoantibody responses. Other strains also developed CII- 
specific T cell responses and high titre antibodies but did not develop disease, suggesting 
that the presentation of specific peptides by disease-relevant MHC molecules may induce 
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a qualitatively different response in T cells resulting in disease (Wooley et al., 1981). H- 
2r strains were later also shown to be susceptible to disease induced with bovine or 
porcine CII but not chick (Wooley et al., 1985). The T cell determinants associated with 
susceptibility to disease have been characterised in detail. In H-2q mice, strong T cell 
responses to the peptide 260-267 exist (Brand et al., 1994) and are associated with 
disease susceptibility. However in H-2r mice, 2 immundominant determinants have 
been identified (Myers et al., 1995). Interestingly although T cell responses to both have 
been shown, disease susceptibility is clearly associated with responses to the less potent 
determinant in terms of T cell proliferation (Myers et al., 1995), again suggesting that 
only certain T cell responses can result in disease. Adoptive transfer of disease by T cells 
to SCID mice has been demonstrated although a booster immunisation was required 
(Hesse and Mitchison, 2000; Kadowaki et al., 1994), and T cell depleting treatments 
alleviate disease (Zhang et al., 2002) underpinning the important pathogenic role of T 
cells in this model. 
1.6.2 Human HLA transgenic mice 
The MHC encodes large numbers of immunologically active molecules in addition to 
HLA molecules, and loci in close proximity to each other exhibit linkage disequilibrium 
resulting in the formation of extended haplotypes (Wilson et al., 1993). Hence a major 
problem in the analysis of disease associations with HLA has been isolating the 
contribution of an individual HLA type to disease susceptibility (Hall et al., 1999). The 
development of transgenic mice expressing human CD4 and the disease-associated 
DRB 1 *0401 or disease-neutral DRB 1 *0402 in the absence of murine class II molecules 
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has provided a unique in vivo model wherein the effects of individual DR molecules on 
immune responses can be investigated in isolation (Fugger et al., 1994). The use of this 
approach is illustrated by studies of transgenic mice expressing DRB 1 *0401 or 
DRB 1 *0402 immunised with the candidate antigen human cartilage glycoprotein 39 (see 
below) (Cope et al., 1999). After immunisation a panel of T cell hybridomas was raised 
from draining lymph nodes and their specificities analysed by measurement of 
proliferative responses to whole protein and pools of overlapping synthetic peptides 
spanning the whole molecule. Three immunodominant epitopes in the context of 
DRB 1 *0401 and two completely different epitopes in the context of DRB 1 *0402 were 
defined (Cope et al., 1999). These three epitopes were the same peptides previously 
shown to activate T cells from patients with RA (Verheijden et al., 1997). These results 
clearly demonstrate that disease associated DR alleles present different sets of peptides 
derived from the same antigen compared to disease non-associated alleles, and that the 
theoretical predictions of peptide binding to DR molecules are applicable in vivo. 
Another important observation made in the above system, corroborating studies of CIA is 
that DR molecules can have antigen-specific effects on the qualitative nature of immune 
responses. Hence following immunisation of DRB 1 *0401 mice, when T cells were 
restimulated with the relevant immunodominant peptides prominent production of IFNy 
and TNF was seen, however when T cells from DRB 1 *0402 mice were stimulated with 
the appropriate immunodominant peptides little cytokine production was seen, despite 
equivalent proliferative responses as measured by thymidine incorporation (Cope et al., 
1999). Spontaneous arthritis has not been observed in DRB 1 *0401/murine class II 
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deficient transgenic mice however they are susceptible to collagen-induced arthritis 
(Andersson et al., 1998) suggesting that DRB 1 *0401 is capable of promoting the 
development of arthritogenic anti-CII specific T cells. 
1.6.3 The K/BxN mouse 
The K/BxN mouse represents a MHC restricted spontaneous model of arthritis (Kouskoff 
et al., 1996). The original KRN transgenic strain expresses a single TcR derived from a 
T cell hybridoma with specificity for a single peptide of bovine ribonuclease restricted by 
lAk. Transgene-expressing T cells overwhelm central tolerance induction mechanisms 
and make up a significant proportion of aJ T cells in the periphery. Crossing this strain 
onto the NOD background resulted in a strain designated K/BxN (KRN/B 10 x NOD) that 
developed an inflammatory arthritis with complete penetrance (Kouskoff et al., 1996). 
Susceptibility to arthritis was demonstrated by backcrossing and transgenic experiments 
to be dependent on the NOD-encoded IAg7 MHC class II specificity (Kouskoff et al., 
1996). Subsequently the KRN T cells were shown to cross react with a peptide of the 
ubiquitous enzyme glucose-6-phosphate isomerase (G6PI) presented by IAg7, and the 
disease shown to be transferable purely with specific IgG against G6PI (Matsumoto et al., 
1999). Hence the relevance of this system for the paradigm discussed above is in 
demonstrating that a joint-specific disease can be dependent on the presentation of a 
specific peptide by a disease-linked MHC molecule. 
The structural and functional studies described above provide clear evidence that the 
presentation of unique peptides to T cells could be a possible basis for the susceptibility 
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to RA associated with the shared epitope and strongly implicate T cells as being 
important in RA. However they do not provide any direct evidence for the pathogenic 
involvement of T cell responses in human disease. In the following sections the 
properties of T cells in human disease shall be considered in relation to a possible 
pathogenic role. 
1.7 T cells in RA 
1.7.1 Properties of T cells in RA 
Rheumatoid synovial membrane is infiltrated with T cells, and topographical 
arrangements have been noted bearing marked resemblance to those seen in primary 
lymphoid tissue (Iguchi and Ziff, 1986; Kurosaka and Ziff, 1983; Young et al., 1984). 
Structures indistinguishable from germinal centres are seen in some patients (Klimiuk et 
al., 1997). However the composition and structure of the infiltrate is variable and stromal 
components can dominate the picture (Kurosaka and Ziff, 1983). It is possible that these 
variations may represent different stages of disease as prospective studies are difficult to 
perform. Many studies have attempted the characterisation of synovial T cells in terms of 
cell surface marker expression, cytokine production and clonality based on T cell 
receptor gene segment usage. Synovial T cells are predominantly CD4 positive, and 
express cell surface markers such as LFA1, CD69 and CD45RO typical of memory cells 
(lannone et al., 1994). This is to be expected as it is only after activation that T cells 
acquire cell surface molecules such as the integrin VLA4 necessary for interaction with 
non-lymph node endothelium and therefore the ability to traffic through non-lymphoid 
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tissues. However contrary to primed T cells in peripheral blood or T cells activated in 
vitro, they express very low levels of CD25, the IL-2 receptor (Iannone et al., 1994). 
Furthermore the typical T cell cytokines IL-2 and IFNy have been very difficult to detect 
in the synovium, although more recently IFNy protein and mRNA have been 
demonstrated in synovial tissue and peripheral blood.. This unusual phenotype is likely 
to reflect continuous recruitment of T cells into the joint (lannone et al., 1994) and 
specific survival signals in the highly specialised microenvironment of the synovium 
(Akbar and Salmon, 1997). Additionally it has been shown that ex vivo synovial T cells 
are hyporesponsive to stimulation via the CD3/TcR complex. A substantial body of work 
now exists to support the view that chronic exposure of synovial T cells to TNF, as well 
as other aspects of the synovial cytokine and cellular milieu may explain these 
observations (Cope, 2002). 
There is some evidence to support the view that differentiated memory T cells in RA 
corresponding to the Thl subtype may be pathologically relevant (Skapenko et al., 1999) 
and type 2 cytokines such as IL-4 could be used to regulate their function. Clonal 
expansions of T cells in synovial tissue and peripheral blood have been reported in RA by 
many authors (Weyand and Goronzy, 1999). These expansions appear stable over time 
and are common to multiple involved joints in an individual. Some expanded clonotypes 
seem to correspond to a subset of CD4+CD28- T cells that are more prone to 
autoreactivity (Schmidt et al., 1996). Such clonal expansions have been reported in 
normal individuals and occur more frequently with age (Weyand et al., 1998a). No 
common antigen specificity or T cell receptor gene segment usage has been identified in 
RA suggesting that the observed clonal expansions may not be antigen-driven but rather 
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reflect defects in T cell homeostasis and the stringent requirements for survival and 
differentiation in the joint (Weyand and Goronzy, 1999). 
1.7.2 Anti-T cell therapies 
Although much is known about the properties of synovial and peripheral T cells in RA 
their involvement in disease initiation or persistence remains implied. The ultimate test 
of the importance of T cells in pathogenesis is the efficacy of therapy directed at T cells. 
Several early anti-lymphocyte modalities including lymphocytapheresis (Emery et al., 
1986), total lymphoid irradiation (Helfgott, 1989), thoracic duct drainage (Ueo et al., 
1979) and cyclosporin A (Weinblatt et al., 1987) have been shown to be effective. More 
recently a number of studies have investigated the use of specific monoclonal antibody 
therapy directed at T cells (Choy et al., 1998; Isaacs, 2001). Many small-scale open-label 
studies have suggested that these agents are efficacious, however a number of problems 
have been encountered, particularly the production of human anti-mouse antibodies and 
profound lymphopaenia. These effects have been unpredictable and reflect specific 
properties of the individual antibodies employed; ongoing work in this field is focussed 
on defining the properties responsible for such effects and engineering variants for 
clinical testing. T-cell receptor peptide vaccination offers a method of targeting clones of 
T cells by directing a therapeutic immune response towards clonal expansions of T cells 
bearing particular a/ß receptors. An initial study reported no adverse effects and clinical 
improvement and further studies are planned (Moreland et al., 1998). 
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Taking all the available evidence into account, there is much to support the view that T 
cells are important in the pathogenesis of rheumatoid arthritis, whether due to antigen- 
specific mechanisms or antigen non-specific recruitment to a unique site of inflammation. 
1.8 T-B cell interactions in RA 
The production of high-affinity antibodies by B cells is a CD4+ T cell-dependent process. 
T cell help provided by direct cell-cell interaction involving for instance the CD40- 
CD40L pair and also secreted mediators is required for class switching and affinity 
maturation due to somatic hypermutation (Clark and Ledbetter, 1994). In addition B 
cells can act as highly efficient antigen-presenting cells by internalising soluble antigens 
via high affinity surface immunoglobulin and presentation to T cells in the context of 
class II MHC molecules (Clark and Ledbetter, 1994). Rheumatoid factor producing B 
cells characteristic of RA may have such a function (see below and figure 1), and indeed 
B cells have been shown to play such a role in animal models of autoimmune disease 
such as NOD (Falcone et al., 1998) and MRL/lpr (Chan et al., 1999) mice. There is 
considerable evidence for the interaction of T and B cells in RA. Germinal centre-like 
structures occur in RA synovium implying close functional relationships between B and 
T cells and APCs such as follicular dendritic cells (Randen et al., 1995). B cells from RA 
synovium show evidence of class switching (Rudolphi et al., 1997) as well as somatic 
hypermutation (Gause et al., 1995) known to be T cell dependent processes. Hence the 
study of autoantibodies in RA represents a potential approach to identify T cell epitopes. 
The relative ease of analysis of autoantibodies as compared to T cells makes them 
potentially very useful as diagnostic or prognostic markers, or tools to attempt to define 
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subgroups of patients with related clinical or pathogenetic features. These considerations 
have driven a large body of work attempting to characterise autoantibody responses in 
RA. 
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Figure 1. The T-B cell paradigm in rheumatoid arthritis 
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1.9 Autoantibody systems in RA 
A number of autoantigen systems have been described in RA and their clinical 
associations and role in pathogenicity or as markers of disease examined. These are 
summarised in table 2 and discussed below. 
Table 2. A summary of well characterised autoantigens in rheumatoid arthritis 
Antibody prevalence T cell References 
% responses' 
Rheumatoid factor 60-80 ND 
Type II Collagen 10-30 y 
Hcgp 39 ND Y 
Citrullinated antigens 30-50 ND 
RA33 / HnRNPA2 30 ND 
Calpastatin 10-50 ND 
Heat shock proteins 5-10 y 
p68 / BiP 30-64 y 
gp 130-RAPS 73 ND 
Follistatin-related protein 30 ND 
CTLA-4 18 ND 
eEF 1-alpha 1 21 ND 
Lactoferrin 10 ND 
Denatured aldolase a 10 ND 
Osteopontin 15 ND 
Table 2. ND not determined, Y yes, N No 
See text 
See text 
See text 
See text 
See text 
See text 
(Tishler and Shoenfeld, 1996) 
(Blass et al., 2001) 
(Cocrigall et al., 2001) 
(Tanaka et al., 2000) 
(Tanaka et al., 1998) 
(Matsui et al., 1999) 
(Ditzel et al., 2000) 
(Locht et al., 2000) 
(Ukaji et al., 1999) 
(Sakata et al., 2001) 
'Measurement of T cell responses to antigens varies considerably in terms of the site from which cells were 
isolated, whether or not ex vivo priming was carried out and the method used for determining response, 
hence frequencies are not directly comparable and Y or N therefore denotes presence or absence of 
responses. 
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1.9.1 Rheumatoid factors 
Rheumatoid factors (RFs), the first described human autoantibodies (Waaler, 1940) are 
directed at the Fc region of IgG and are usually of IgM isotype. They are detectable in up 
to 10% of normal individuals, 70-80% of patients with RA and in other systemic diseases 
such as Sjogren's syndrome and many systemic infections (Tighe and Carson, 2001). 
Rheumatoid factors and the B cells that synthesise and secrete them are believed to have 
a physiological role as part of the immune system. However RFs from healthy 
individuals and patients with RA differ considerably. Rheumatoid factors in healthy 
individuals are synthesised by CDS+ B cells, exhibit low affinity for IgG, polyreactivity 
and a low ratio of replacement to silent mutations in their CDRs (Borretzen et al., 1997; 
Mantovani et al., 1993) suggesting the presence of a mechanism to suppress the affinity 
maturation of RFs. This is supported by the observation that high affinity RFs are deleted 
in mice (Tighe et al., 1995). In rheumatoid synovium, B cells produce high affinity RFs 
with multiple replacement mutations in their CDRs (Borretzen et al., 1997) indicating a 
process dependent on T cell help. A crucial role for CD40 signalling on the production 
of RF in a transgenic mouse model has been demonstrated (Kyburz et al., 1999) 
suggesting that bystander T cell help could drive RF synthesis. In addition synoviocytes 
themselves can support the survival and differentiation of B cells (Edwards et al., 1997). 
Hence in RA synovium RF-producing B cells could encounter a milieu which would 
support their survival and provide the T cell help necessary for the production of high 
affinity RFs (Edwards and Cambridge, 1995) (see figure 1). There is evidence that they 
could contribute to disease by the formation of immune complexes (Edwards and 
Cambridge, 1998) and complement fixation (Brown et al., 1982), and also by functioning 
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as highly efficient antigen presenting cells (Tighe et al., 1993). The correlation of RF 
status and progression of joint damage in RA (Masi et al., 1976) support a role in 
pathogenesis although they are by no means an absolute requirement for severe disease 
and joint destruction. 
1.9.2 Type II Collagen 
The possible importance of immune responses to type II collagen (CII) was first 
suggested nearly thirty years ago. The specific expression of this molecule in articular 
cartilage as well as its ability to induce a destructive arthritis in experimental animals 
made it an attractive candidate autoantigen in human RA (see above). Antibodies to 
native and denatured CII have been demonstrated in serum of patients with RA (10-30%) 
(Clague et al., 1994; Morgan et al., 1987) as well as synovial fluids, and collagen- 
anticollagen immune complexes described in synovial tissue (Clague and Moore, 1984). 
A dominant epitope of anti-CII antibodies has been identified (Kraetsch et al., 2001). T 
cell responses have been found in approximately 50% of antibody positive patients 
(Snowden et al., 1997). Antibodies to CII are present early in the disease course and 
appear to decline with time, and may be predictive of a more severe outcome (Cook et 
al., 1996). However T cell responses to CII are also found in 37% of normal individuals 
(Snowden et al., 1997), many patients do not demonstrate any form of immune response 
to CII and no major associations with clinical parameters have been described. Attempts 
to induce tolerance in patients with RA by the oral administration of collagen have had 
limited success (Barnett et al., 1998). Hence the relevance of anti-CII T cell responses 
and autoantibody remains unclear. 
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1.9.3 Human cartilage glycoprotein 39 (HCgp39) 
HCgp39 (also known as YKL-40) is a major secreted product of articular chondrocytes 
and synovial fibroblasts (Hakala et al., 1993), and based on structural homology is a 
member of the glycohydrolase family 18, which comprises a large number of pro- and 
eukaryotic chitinases (Renkema et al., 1998). Its physiological role is unknown, however 
it does not possess the enzymatic activity of the other chitinases (Hakala et al., 1993) and 
a recent report has demonstrated that it can promote the growth of synoviocytes and 
fibroblasts (Recklies et al., 2002). Initial interest in this molecule as a putative 
autoantigen stemmed from the observation that HCgp39 mRNA was expressed in RA 
synovium and cartilage but not in normal joints (Hakala et al., 1993). Algorithms for 
predicting peptide binding to disease-associated HLA DR alleles were used to search for 
potential T cell epitopes within this molecule and proliferative T cell responses to four 
peptides measured. Responses were demonstrated in 9/18 RA patients and 2/11 controls. 
In addition immunization of BALB/c mice with HCgp39 induced a polyarthritis that was 
preventable by prior nasal administration of the antigen suggesting a possible pathogenic 
role for autoimmunity directed against HCgp39 (Verheijden et al., 1997). T cell 
responses against HCgp39 have also been described in patients with osteoarthritis and 
inflammatory bowel disease (Vos et al., 2000). Recent studies have suggested a wider 
role for HCgp39 in inflammatory processes and tissue remodelling. Serum 
concentrations are elevated in patients with RA and correlate with disease activity 
(Johansen et al., 1999). Synovial fluid levels are 10-fold higher suggesting local 
production and direct involvement in joint inflammation and tissue breakdown (Johansen 
19 
et al., 1993). HCgp39 is synthesised at other sites of inflammation or involution 
including cirrhotic liver (Johansen et al., 2000), post-lactational breast tissue (Rejman and 
Hurley, 1988) and by cells of the monocyte/macrophage lineage (Kirkpatrick et al., 
1997). A recent study demonstrated that intranasal administration of HCgp39 resulted in 
the amelioration of arthritis induced in DBAI/j mice with an unrelated antigen, type II 
collagen, suggesting the possibility of a more generalized effect on immune regulation 
(Joosten et al., 2000). The involvement of HCgp39 therefore in pathogenic processes in 
RA is clear, although to what extent this is related to autoimmunity is not established and 
remains a subject of considerable interest. 
1.9.4 Citrullinated antigens - anti-keratin antibody (AKA), anti perinuclear factor 
(APF), anti-fillagrin antibody (AFA), citrullinatedpeptides and Sa 
Anti-perinuclear factor (APF) was first described more than thirty years ago by the 
demonstration of a perinuclear staining pattern with RA sera using indirect 
immunofluorescence on buccal mucosal cells (Nienhuis and Mandema, 1964), and anti- 
keratin antibody (AKA) by a similar technique using rat oesophageal sections as substrate 
(Young et al., 1979). Both factors were found to be highly specific for RA and hence a 
role in pathogenicity suggested. A large body of work over the last ten years has shed 
considerable light on the targets of these antibodies. Both factors were shown to share 
specificity for the cytokeratin-filament aggregating protein fillaggrin (Sebbag et al., 1995; 
Simon et al., 1993). Moreover this specificity was shown to be dependent on an 
enzymatic post-translational modification, the conversion of arginine residues to 
citrulline by the enzyme peptidylarginine deiminase (Girbal-Neuhauser et al., 1999). A 
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great diversity of synthetic cyclical citrullinated peptides (CCP) based on citrulline- 
containing motifs of fillagrin have been shown to bind to APF/AKA positive sera 
(Schellekens et al., 1998) emphasising the importance of citrullinated residues as key 
antigenic determinants recognised by these antibodies. Recent work has suggested the 
targets of these antibodies are deiminated forms of a and ß fibrin (Masson-Bessiere et al., 
2001), which is interesting because fibrin is found abundantly in rheumatoid synovium 
and has prompted speculation of direct pathological involvement. This is supported by 
the observation of local production of AKA in RA synovium (Masson-Bessiere et al., 
2000). There is also one report of intracellular citrullinated proteins in RA synovium and 
a suggestion that the presence of citrullinated proteins may be specific for RA (Baeten et 
al., 2001). 
Anti-Sa was first described by immunoblotting of RA sera using spleen and placental 
extracts as substrate (Despres et al., 1994) and was found to have a similar high 
specificity for RA (Hueber et al., 1999). The Sa antigen has been identified as the 
cytoskeletal protein vimentin, and once again antigenicity found to be dependent on 
citrullination (Menard et al., 2000). A strong correlation has been found between the 
presence of anti-Sa and anti-CCP (Goldbach-Mansky et al., 2000). These data suggest 
that APF, AKA, AFA, anti-Sa and anti-CCP are an overlapping group of antibodies 
directed against citrullinated antigens. Although earlier studies suggested a predictive 
value for more severe disease, a recent large study of patients with early synovitis 
suggested that testing was probably of little value over and above traditional assessments 
(Goldbach-Mansky et al., 2000). Anti-Sa however did seem to define a subgroup of male 
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patients with a more severe phenotype (Goldbach-Mansky et al., 2000). Considered as a 
whole, there is much evidence to support the view that antibodies to citrullinated antigens 
are important in some aspect of the pathogenesis of RA, although their role has not as yet 
been fully elucidated. 
1.9.5 Anti-RA33/hnRNPA2 
Antibodies to the 33kDa A2 protein of the heterogeneous nuclear ribonucleoprotein 
complex (anti-RA33 or anti-hnRNP A2), a component of the spliceosome were first 
demonstrated in approximately 35% of patients with RA by Western blotting (Hassfeld et 
al., 1989). They are not specific however occurring in 20% of patients with SLE and 40- 
60% with MCTD, usually concomitantly with antibodies to U 1-snRNP or Sm unlike in 
RA where these antibodies do not occur (Hassfeld et al., 1995). The major autoantibody 
binding sites have been shown to be conformation-dependent and found to be different in 
MCTD patients from RA and SLE (Skriner et al., 1997). Interestingly anti-RA33 has 
been shown to occur in two experimental models of arthritis, in TNF-transgenic mice and 
in the arthritis prone MRL/lpr mice (Steiner et al., 1997). The presence of anti-RA33 in 
SLE appears to define a subset of patients with destructive arthritis emphasising the link 
with joint pathology (Richter Cohen et al., 1998). Although shown to be present early in 
the disease, anti-RA33 has not been shown to have any predictive value for disease 
severity or progression (Goldbach-Mansky et al., 2000). 
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1.9.6 Antibodies to calpastatin 
Calpastatin is a natural inhibitor of the calpains, a family of intracellular calcium- 
dependent cysteine proteases unique because of their cytosolic rather than lysosomal 
location. Calpains are over-expressed in diseased synovial tissue (Szomor et al., 1995; 
Yamamoto et al., 1992) and secreted calpains can degrade components of articular 
cartilage (Suzuki et al., 1992). Two groups independently described antibodies to 
calpastatin in approximately 50% of RA sera and although not specific for RA they occur 
at a higher frequency than in connective tissue diseases (Despres et al., 1995; Mimori et 
al., 1995). It has therefore been postulated that autoantibodies to calpastatin may 
potentiate joint destruction by interference with the calpain-calpastatin interaction 
(Menard and el-Amine, 1996). Some support for this comes from the in vitro observation 
that calpains are released from calpain-calpastatin complexes in the presence of RA sera 
(Mimori et al., 1995). Antibodies to calpastatin however are not associated with disease 
severity, and more recent studies have suggested they may be less frequent than 
previously believed (Lackner et al., 1998). The importance therefore of anti-calpastatin 
antibodies in RA remains unclear. 
1.9.7 Other autoantigens in RA 
There are reports of autoantibody and less frequently T cell responses to many other 
antigens although characterised in less detail than those discussed above. These are 
summarised in table 2. At the current time the importance of many of these remains a 
subject requiring further study. 
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1.10 Autoantibodies as markers of disease 
It is clear that the presence of autoantibodies is a feature of RA and despite some overlap 
the serological profile of RA is distinct from other diseases such as SLE (Blass et al., 
1999). The production of autoantibodies is a prominent feature of many diseases 
including certain malignancies, and in the vast majority they are not directly pathogenic. 
Many highly specific disease associations with autoantibodies exist and are likely to 
reflect unique aspects of the pathology in each case (Czaja and Homburger, 2001; 
Targoff, 2000). Such autoantibodies have proven to be very important diagnostic 
markers. Hence it is possible that autoantibodies may be useful diagnostic or prognostic 
markers in RA especially in early disease when it is difficult to differentiate self-limiting 
synovitis from potentially persistent and destructive disease (Kim and Weisman, 2000) 
and the importance of early treatment is well established (Fries et al., 1996; Stenger et al., 
1998). Data on sensitivity and specificity for the diagnosis of RA is now available for 
most of the better-characterised antibodies (table 3). A study of a well-characterised 
cohort of 238 patients with arthritis of recent onset concluded that although anti-Sa, AFA 
and anti-CCP all had a high diagnostic specificity there was little value over 
measurement of rheumatoid factor alone (Goldbach-Mansky et al., 2000). A more recent 
study of 179 patients with established disease confirmed their high diagnostic specificity 
but demonstrated again that RF status was a better predictor of disease severity (Bas et 
al., 2002). 
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Table 3. Diagnostic value of autoantibodies in early arthritis. 
Sensitivity Specificity PPV 
Rheumatoid factor 0.66-0.75 0.74-0.87 0.80 
AFA 0.33 0.93 0.79 
Anti-Sa 0.22 0.98 0.88 
Anti-CCP 0.41-0.68 0.91-0.96 0.78 
AKA 0.26-0.46 0.84-0.94 0.56 
RF+ and one or more of above 0.50 0.96 0.90 
RF- and one or more of above 0.31 0.73 0.26 
Table 3. Diagnostic value of autoantibodies for rheumatoid arthritis in 238 patients with early arthritis. 
PPV, positive predictive value. (Modified from Goldbach-Mansky et al 2000 and Bas et al 2002) 
Any analysis of RA must take into account the observed heterogeneity of disease 
(Weyand et al., 1998b), hence it may be possible to define subsets of patients on the basis 
of serotype and investigate the hypothesis that they represent subgroups of patients 
sharing common pathological mechanisms or clinical phenotype. For instance in the 
study described above, anti-Sa defined a group of male patients with more severe disease 
(Goldbach-Mansky et al., 2000). Antibodies to eukaryotic translation elongation factor 1 
alpha are much more frequent in patients with Felty's syndrome (66%) than non-Felty's 
RA (21 %) (Ditzel et al., 2000). Anti-aldolase A has been associated with the presence of 
bone erosions (Ukaji et al., 1999). It may therefore be possible to gain insights into 
relevant pathophysiological processes from the analysis of autoantibodies as well as 
develop markers with a predictive value for particular aspects of disease. 
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For these reasons, much interest continues in the isolation and characterisation of 
autoantigens in rheumatoid arthritis. From table 2 it can be seen that antibody responses 
to a number of self-proteins have been characterised and the significance of a number of 
these remains unclear. The majority of these studies have used patients with established 
disease and it is well known that immune responses including those to self-antigens 
diversify over time to involve multiple epitopes within single molecules and other 
proteins (intra- and inter-molecular determinant spreading) (Yu et al., 1996). It is easy to 
envisage this occurring at a site of inflammation such as rheumatoid synovium as a result 
of antigen release from damaged tissue and subsequent uptake by antigen-presenting cells 
and presentation by class II molecules. Indeed such a cascade of events has been 
postulated to be an important process in the development of autoimmunity 
(Lanzavecchia, 1995). Hence if patients with early RA were studied a different profile of 
antigens might be encountered. These may be more relevant to disease initiation or better 
predictors of severity or outcome. 
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1.11 Aims of this thesis 
The aims of this thesis were : 
1. To investigate the use of a novel phage display system for the isolation and 
characterisation of novel autoantibodies from the sera of patients with established 
and early rheumatoid arthritis. 
2. To characterise antibody responses to other recently described putative 
autoantigens in rheumatoid arthritis. 
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2 Cloning autoantigens from a fibroblast-derived cDNA library 
expressed on the surface of filamentous bacteriophage 
2.1 Introduction 
2.1.1 cDNA cloning is an effective method for characterising novel antigens in 
rheumatoid arthritis 
Methods for the characterisation of novel antigens all rely on the detection of an 
interaction between antibody from sera or synovial fluid of interest and a complex 
mixture of potential ligands. Earliest methods include indirect immunoflourescence 
using fixed cells or tissue sections as antigenic substrate (Nienhuis and Mandema, 1964; 
Young et al., 1979) and more recently Western blotting against a variety of target tissues 
(Blass et al., 1995; Lafyatis et al., 1992). The obvious drawback with such techniques is 
that the targets of these antibodies subsequently require identification. Higher resolution 
separation of proteins in a complex mixture such as a tissue homogenate can be achieved 
using 2-dimensional gel electrophoresis and individual proteins identified by MALDI- 
TOF mass spectrometry (Corrigall et al., 2001), however all these techniques rely upon 
the target antigen being expressed in the tissue analysed at a high enough level for 
detection. The isolation of antigens by screening of eDNA libraries offers the advantage 
that the identity of a gene product interacting with the serum can be established by 
sequencing, and for this reason screening of bacteriophage, % cDNA expression libraries 
with RA sera has been attempted by several investigators with some success (Despres et 
al., 1995; Mimori et al., 1995; Tanaka et al., 2000; Tanaka et al., 1998). This approach 
also has limitations; proteins may lose antigenicity as a result of denaturation and binding 
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to solid supports inherent in the procedure, the number of clones that can be screened 
with reasonable effort and resources is limited to approximately 1x 106, and relatively 
large quantities of serum are required. 
2.1.2 Phage display technology 
Phage display was first described in the 1980s (Smith, 1985) and offers a powerful 
alternative cDNA cloning methodology with a number of theoretical advantages over 
conventional cloning strategies. In essence foreign DNA fragments are expressed as 
fusion proteins with filamentous phage gene III or gene VIII, which encode coat proteins 
(see figure 2). The fusion proteins are then incorporated into mature phage particles, 
which retain infectivity and display the fusion protein on their surface in a form 
accessible to antibody. Phage expressing fusion proteins that bind the antibody of interest 
can be enriched from a complex mixture of 1010 to 10" clones by rounds of affinity 
selection on ligand-coated surfaces and propagation in host bacteria, a procedure now 
often referred to as "panning". The physical linkage of the fusion protein to its encoding 
DNA in the phage particle allows identification by sequencing. Random peptide libraries 
(Parmley and Smith, 1988), libraries of DNA-binding proteins (Rebar and Pabo, 1994) 
and both single chain antibody (McCafferty et al., 1990) and F(Ab) fragments (Barbas et 
al., 1991) have been expressed on the surface of phage and used to characterise a number 
of receptor-ligand interactions in this way. 
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Figure 2. The structure of filamentous phage 
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Figure 2. Each particle carries between 3 and 5 copies of the gene III protein, the n-terminal domain of which mediates 
adsorption to the pilus, and c-terminal domain which is important for assembly. The number of copies of gene VIII is 
determined by the length of DNA contained by the particle. 
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One group has previously attempted screening of phage display libraries with RA sera 
and synovial fluids (Dybwad et al., 1993; Dybwad et al., 1995; Dybwad et al., 1996). 
Using a random peptide library displayed as a gene VIII fusion peptide epitopes that 
bound antibodies in sera and synovial fluids were successfully identified. Homologies 
between immunoselected peptides and viral proteins were noted, however the utility of 
these antibodies as diagnostic or prognostic markers was not established. 
2.1.3 The pJuFo system: a methodology for the display of products of cDNA libraries 
on phage surfaces. 
The phage display systems used for the expression of functional immunoglobulin 
fragments such as pCBAK8 (Kang et al., 1991) and pComb 3 (Barbas et al., 1991) rely 
on the use of two independent promoters simultaneously controlling the expression of the 
Ig heavy chain as an N-terminal coat fusion protein, and the light chain as a secreted 
molecule. Pe1B leader sequences target the preproteins to the bacterial periplasm where 
they are able to form functional heterodimers. Such systems however were not suitable 
for the expression of the products of whole cDNA libraries, as the presence of in-frame 
stop codons in the 3' untranslated regions of eukaryotic genes would prevent the 
expression of the phage coat protein. The pJuFo system (Crameri and Suter, 1993) 
employs the ability of the leucine zippers of Jun and Fos to form a heterodimer 
(Kouzarides and Ziff, 1988) to covalently link the products of cDNA libraries to the 
phage gene III protein (figure 3), thereby establishing a system theoretically capable of 
allowing the enrichment of ligands from phage-displayed cDNA libraries. The efficacy 
of this vector has been demonstrated by the selective enrichment of allergens of 
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Aspergillusfumigatus from a cDNA library using IgE from allergic patients (Crameri and 
Blaser, 1996). 
The work described below represents attempts made to isolate novel antigens in by 
panning of a fibroblast cDNA library expressed using the pJuFo system with IgG from 
sera of patients with RA. 
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Figure 3. Assembly of the piuFo phage particle 
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Figure 3. (1) In the cytoplasm of' host bacteria la(-Z promoters drive expression of' both jun-gil I and fos-cDNA product 
fusion proteins and pelB leader sequences direct transport across the inner membrane. (2) The jun-fos fusions 
hcterodimcrisc in the bacterial pcriplasm and the non-covalcnt association is further stabilised by disulphide bonds, which 
f'orm as a result ol'engincered cysteinc residues. The fusion proteins are then incorporated into mature phage particles as a 
result of the supply of other coat proteins by helper phage and secreted into the extracellular medium (3). 
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2.2 Materials and methods 
2.2.1 Vectors, helper phage and host strains 
Resource Source 
pJuFo Kindly provided by Dr Reto Crameri 
VCS M 13 helper phage Stratagene, La Jolla, CA 
XL-1 Blue MRF' strain E Coli Stratagene, La Jolla, CA 
2.2.2 Libraries 
The fibroblast-derived phage cDNA library was created by the in-vivo excision (Short et 
al., 1988) of a fibroblast cDNA library in the UNIZAP-II 1 vector obtained commercially 
(Stratagene, La Jolla, CA), restriction with Bg1II/Xba I and subcloning into the pJuFo 
vector. Further details of methods for library construction are provided in chapter 3. 
2.2.3 Essential elements ofpJuFo and filamentous phage biology. 
The essential elements of the pJuFo vector are shown in figure 3. In addition to the jun- 
gene III and fos-cDNA fusions, it contains both the phage fl origin and the ColE 1 origin 
allowing it to be propagated as a plasmid in bacteria as well as packaged into phage 
particles (phagemid). It does not encode other coat protein genes however; hence the 
production of mature phage particles requires superinfection with a helper strain that 
provides the necessary coat proteins. Host cells co-infected with a recombinant pJuFo 
molecule and helper produce phage particles composed of a mixture of wild-type and 
recombinant gIII product and wild-type coat proteins. A single phage particle will only 
contain a single DNA molecule hence a mixture of particles containing wild-type and 
phagemid genomes will be produced. The presence of the ampicillin resistance marker 
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allows selection of host bacteria infected with recombinant phage rather than helper 
alone. 
2.2.4 Titration ofphage 
Filamentous phage infection of host cells occurs by adsorption of the phage particle to the 
F pilus of the bacterium, an interaction mediated by the phage gene III protein. The 
genome is then passed through the pilus into the host cell. Pilus genes are located on the 
F episome which also encodes tetracycline resistance, hence host cells must be grown in 
tetracycline-containing media in order to retain the F episome and infectability. 
In order to titre the phage, a single colony of XL- I blue MRF streaked from a glycerol 
stock onto a LB-agar plate containing 12gg/ml tetracycline was used to inoculate I Oml of 
LB-tet and the culture grown overnight to late logarithmic phase. Dilutions of phage 
stock in LB were then combined with 1-2m1 of host cells and incubated together at room 
temperature for 15 minutes to allow phage to adsorb onto host cells. Between 2 and 20gl 
of infected host cells from each dilution were spread onto LB-agar plates containing 
12gg/ml tetracycline and I OOgg/ml ampicillin. After incubation for 16 hours at 37'C the 
number of colonies on each plate were counted. The titre of the original phage stock was 
then calculated according to the formula: (number of colonies) x (total volume of infected 
cells/volume plated) x (dilution factor) x (Iml/volume of phage dilution used for 
infection) and expressed as colony-forming units (cfa) per ml. Uninfected. host and cells 
infected with defined amounts of a library of known titre were also plated simultaneously 
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as controls for contamination of the host with an ampicillin-resistant strain and host 
infectability respectively. 
2.2.5 Growth and propagation ofphage 
A high titre phage stock was produced by the infection of 1-2ml. of host cells with pJuFo 
as described above. After adsorption of phage I Oml of fresh LB-medium without 
antibiotic was added to the infected host cells and the culture shaken at 37'C for I hour to 
allow expression of resistance genes. The 10ml culture was superinfected with VCS M13 
helper phage at a multiplicity of infection of 20: 1 and incubated at room temperature for 
IS minutes. The culture was then added to I 00ml of fresh LB-mediurn containing 
12gg/ml tetracycline, I OOgg/ml ampicillin and I Ogg/mI kanamycin. and grown overnight 
with shaking at 37T. During this time host cells infected with pJuFo secrete mature 
phage particles into the culture medium. The culture was freed of viable bacterial cells 
by heating to 65'C for 15 minutes followed by centrifugation. The supernatant was 
retained and phage particles precipitated by the addition of 0.15 volumes each of 40% 
PEG 8000 and 5M NaCl. After incubation on ice for one hour phage particles were 
collected by centrifugation. The pellet thus obtained was resuspended in Iml of sterile 
PBS, and clarified of bacterial debris by centrifugation in a microfuge. The phage stock 
was stored at -20'C. Stocks with titres of 10'. to I O"/ml of culture supematant were 
obtained in this way. 
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2.2.6 Patients and sera 
Two pools of sera were used for panning experiments described. The first pool consisted 
of serum from ten patients with established RA as defined by the ACR criteria (Arnett et 
al., 1988) of at least 3 years duration, 6 female and 4 male, and an age range of 58-83. 
The second comprised 20 patients with early RA, all within 12 months of onset of 
symptoms. Ethical approval of the South Sheffield Research Ethics Committee for 
collection and use of all sera was sought and granted. 
2.2.7IgG purification 
IgG was purified from pools of sera by affinity chromatography on a protein A-sepharose 
cartridge (Protein A Antibody Purification Kit, Sigma-Aldrich, Gillingham, UK) 
according to the manufacturer's instructions. Immunoglobulin G eluted from the 
cartridge was dialysed twice against 2 litres of PBS for 16 hours each and quantified 
using a modified version of the Bradford dye-binding assay (Bio-Rad Protein Assay, Bio- 
Rad, Herts, UK). Purity was judged to be at least 95% by SDS-PAGE and Coomassie 
blue staining. An example demonstrating typical heavy and light chain bands under 
reducing conditions is shown in figure 4. 
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Figure 4. SDS-PAGE analysis of purified IgG 
Ml 2 
50 kDa- ,s 
30 kDa- - 
ý .: 
Fligure 4. M denotes molecular weight markers, lanes I and 2 separate IgG samples. 
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2.2.8 Panning procedure 
Individual wells of a microtitre plate (Costar 3590, Coming, NY) were coated with 
patient or normal IgG at a concentration of I OOgg/ml in PBS overnight at 4'C. Wells 
were then blocked with 300gl of 5% skimmed milk powder in PBS/tween 0.5% (PBS/trn) 
for I hour at room temperature. During this time approximately 10" du of the phage 
library (501A) were blocked by adding an equal volume of blocking buffer (10% skimmed 
milk/ I% tween with or without 20% glycerol) and rotating for I hour at 4'C. Glycerol 
has been shown to reduce non-specific adsorption and alter the repertoire of phage-ligand 
interactions (Kjaer et al., 1998) and it was for this reason that selection was performed 
both in the presence and absence of glycerol. Blocking buffer was removed from the 
wells; the blocked phage library applied and binding allowed to proceed overnight at 4*C. 
On the next day the phage were removed and the plate washed 15 times by filling each 
well with 200gl of wash buffer (PBS/0.5% tween with or without 10% glycerol) and 
aspirating. Finally the well was rinsed once in PBS, and bound phage eluted by adding 
150gl of O. IM HCI adjusted to pH 2.2 with glycine. After incubation on ice for 10 
minutes the solution was neutralised by the addition of 9gl of 2M Tris. The neutralised 
solution containing eluted phage was (159gl) was used to infect 2ml of XLI Blue MRF' 
as described above. One to I Ogl of infected cells were plated on LB-agar tet-amp plates 
in order to monitor the number of phage eluted. The remainder were amplified as 
described above in order to produce a high titre phage stock that was used for the next 
round of panning. The process was then repeated for each round. Three to 4 rounds of 
panning were generally performed. 
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2.2.9 PCR analysis of panning clones 
PCR employing primers spanning the pJuFo cloning region was used to screen clones for 
the presence of an insert and assess the approximate size of the insert. In order to prepare 
a PCR template a single bacterial colony was picked using a sterile micropipette tip and 
placed in I OOgI of sterile LB medium. The colony was disrupted by vortexing and 50[d 
removed and boiled for 5 minutes using a thermoblock. Bacterial debris was removed by 
centrifugation in a microfage at 130OOrpm for 5 minutes and 1-2gl of the supernatant 
used as PCR template. The remaining 50gl was stored at 4'C until the presence of an 
insert had been confirmed. The following reaction conditions were used: 
Final volume/concentration 
Reaction volume 50gl 
Magnesium concentration 1.5mM 
dNTPs 200mM each 
Primers 200mM each 
The following cycling parameters were used: 
Temperature Time 
Initial denaturation 950C 3' 
Denaturation 950C 30" 
Anneal 550C 30" 
Extension 720C 9091 
No of cycles 36 
PCR products were analysed by agarose gel electrophoresis and ethidiurn bromide 
staining. 
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ZZIO Preparation ofplasmidDNA andsequencing 
Plasmid DNA was prepared from 5ml of overnight culture of each clone grown in LB- 
tet/amp using the WizardTm miniprep kit (Promega, Madison, WI) according to the 
manufacturer's instructions. The DNA was precipitated using ethanol and the pellet 
washed once with 70% ethanol before resuspending in I Ogl of sterile water. Quality and 
approximate quantity of plasmid DNA was assessed by agarose gel electrophoresis and 
approximately 500ng used per sequencing reaction. Sequencing was carried out by the 
core genomics facility of the Division of Genomic Medicine. Sequencing reactions were 
performed using the ABI PRISM BigDy6lm Terminators version 3.0 cycle sequencing 
kit (Applied Biosystems, Foster City, CA) and reaction products analysed using the ABI 
PRISM 377 DNA sequencer. 
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2.3 Results 
Z3.1 Numbers ofphage eluted during rounds ofpanning 
Selective enrichment in panning experiments can be monitored by establishing numbers 
of phage eluted at each round of panning (Crameri and Blaser, 1996). If successful 
selection were taking place it might be expected that numbers of phage eluted at each 
round would increase substantially. Increases of 1000- 100,000 fold over 3 to 4 rounds 
are frequently observed in successful panning using peptide- and antibody-fragment 
libraries. Therefore numbers of phage eluted at each round were established (table 4). 
Table 4. Elution of phage after rounds of enrichment from a fibroblast cDNA 
library 
Panning round 
123 
Established RA IgG 
+glycerol 17790 10034 138040 
-glycerol 3129 1450 3364 
Early RA IgG 
+glycerol 16994 6612 20126 
-glycerol 8642 6380 11600 
Table 4. Numbers represent the mean based on 2 plates per well panned. 
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Z3.2 PCR screening of clonesfromfinal rounds ofpanning 
In addition to an increase in numbers eluted from each round, another method for 
monitoring a panning experiment for evidence of selection is to examine the clonality of 
the eluted phage; an oligoclonal or monoclonal population may arise in response to 
selection by binding to the selecting antibody. Results of screening of 10 randomly 
picked clones from round 3 of each panning series described above by PCR across the 
cloning region are shown in figure 5. 
It can be seen from the figure that in both pannings with established RA IgG a relatively 
diverse mixture of clones appears to exist. In the panning using early RA IgG in the 
presence of glycerol, clones 2,5,8 and 10 appear to have the same size insert. Also of 
note some clones do not generate a PCR product at all, indeed the majority of clones 
(9/10) from the panning using early RA IgG. Attempts to sequence the inserts carried by 
these clones using plasmid DNA and the same sense primer as used for PCR were 
unsuccessful, suggesting these clones possessed a deletion of thefos gene. It appeared 
possible therefore that despite the absence of significant enrichment in terms of phage 
numbers selection may nevertheless have been taking place. It was for this reason that 
the identities of all the inserts carried by the clones shown above was established by 
sequencing. 
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Figure S. PCR amplification of round 3 clones from fibroblast panning. 
Established RA without glycerol 
Early RA without glycerol 
Established RA with glycerol 
Early RA with glycerol 
Mgure 5. Agarosc gel electrophorcsis of PCR products from 10 randomly selected clones of round 3 of each panning 
series. The positions of 500bp and 1000bp molecular weight markers are indicated. 
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Z3.3 Identities of round 3 clonesfrOm each panning series 
Sequencing reactions were perfonned on plasmid DNA and identities established by 
BLAST analysis. These are given in table 5. Most apparent from these sequences is the 
domination of one panning with the same clone encoding a portion of the coding 
sequence and 3' untranslated region of the eukaryotic translation-elongation factor I- 
alpha I gene. This finding was of considerable interest, for as mentioned above, 
autoantibodies; to this molecule have been demonstrated in patients with Felty's 
syndrome but also non-Felty's RA. One of these clones, designated FP 12 ("fibroblast 
panning 12") was characterised in detail. 
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Table 5. Identities of round 3 clones. 
Clone Identity Accession Coding 
Established RA 
Without glycerol 
I Ribosomal protein 1A BC005817 CDS 
2 KLAA0158 D63878 NON CODING 
3 HLA A2 HSHLAA2 NON CODING 
4 mitochondrial M76291. NON CODING 
5 hSIAH2 U76248 NON CODING 
9 beta actin NM001101 NON CODING 
10 myoferlin AF182316 NON CODING 
With glycerol 
I mitochondrial AF382013 NON CODING 
2 EMPTY 
3 ARF I XM096195 NON CODING 
6 Ferritin heavy chain polypeptide I BC015156 CDS 
7 Secreted protein of unknown function BC008823 CDS 
8 mitochondrial AF382011 NON CODING 
Early RA 
Without glycerol 
3 Mitochondrial AF382013 NON CODING 
With glycerol 
2 EEF I alpha- I NMOO1402 CDS 
5 EEF I alpha- I NMOO1402 CDS 
6 EMPTY 
7 RHO GAP XM085082 NON CODING 
8 EEFI alpha-I NMOO1402 CDS 
9 EMPTY 
10 EEF I alpha- I NMOO1402 CDS 
EEF, eukaryotic translation elongation factor. 
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2.3.4 Characteyisation of EEFIaIphal clone. 
Sequence alignment of FP12 and the full-lencyth mRNA for EEFIal is shown in figure 6 and the reading framc In 
of FP12 in figure 7. It can be seen that FP12 encodes the 60 carboxy-terminal amino acids of EEFIal and an 
additional 234 base pairs of the 3' untranslated region up to the poly (A) tail. 
Figure 6. Sequence alignment of EEFlal and FP12. 
141 gatatggttcctggcaagcccatgtgtgttgagagcttctcagactatccacctttgggt 200 
1265 gatatggttcctggcaagcccatgtgtgttgagagcttctcagactatccacctttgggt 1324 
403 DMVPGKPMCVESFSDYPPLG 
201 cgctttgctgttcgtgatatgagacagacagttgcggtgggtgtcatcaaagcagtggac 260 
1325 cgctttgctgttcgtgatatgagacagacagttgcggtgggtgtcatcaaagcagtggac 1384 
423 RFAVRDMRQTVAVGVIKAVD 
261 aagaaggctgctggagctggcaaggtcaccaagtctgcccagaaagctcagaaggctaaa 320 
1385 aagaaggctgctggagctggcaaggtcaccaagtctgcccagaaagctcagaaggctaaa 1444 
443 KKAAGAGKVTKSAQKAQKAK 
321 tgaatattatccctaatacctgccaccccactcttaatcagtggtggaagaacggtctca 380 
1445 tgaatattatccctaatacctgccaccccactcttaatcagtggtggaagaacggtctca 1504 
463 
381 gaactgtttgtttcaattggccatttaagtttagtagtaaaagactggttaatgataaca 440 
1505 gaactgtttgtttcaattggccatttaagtttagtagtaaaagactggttaatgataaca 1564 
441 atgcatcgtaaaaccttcagaaggaaaggagaatgttttgtggaccactttggttttctt 500 
1565 atgcatcgtaaaaccttcagaaggaaaggagaatgttttgtggaccactttggttttctt 1624 
501 ttttgcgtgtggcagttttaagttattagtttttaaaatcagtactttttaatggaaaca 560 
1625 ttttgcgtgtggcagttttaagttattagtttttaaaatcagtactttttaatggaaaca 1684 
561 acttgaccaaaaatttgtcacagaattttgagacccattaaaaaagttaaatgag 615 
1685 acttgaccaaaaatttgtcacagaattttgagacccattaaaaaagttaaatgag 1739 
Figure 6. FP12 sequence is shown above ETEFlal, numbers refer to the nucleotide positions of mRNA sequence NM 
W1402 (gcnbank) or number ot'nuclcotides from the sequencing primer, i. e. 141 represents the end of vector sequence. 
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It is of interest that this clone is not in frame with thefos fusion partner. 
Figure 7. Reading frame of clone FP12. 
DNA: gacgaaaaatccgcgctgcaaaccgaaatcgcgaacctgctgaaagaaaaa 
+3: RKIRAANRNREPAERKR 
+2: TKNPRCKPKSRTC*KKK 
+1: D EKSALQTEIANLLKEK 
DNA: gaaaagctggagttcatcctggcggcacacggtggttgcagatcttctaga 
+3: KAGVHPGGTRWLQIF*N 
+2: KSWSSSWRHTVVADLLE 
+1: E KLEFILAAHGGCRSSR 
DNA: actagtggatcccccgggctgcaggaattcggcacgaggatatggttcctg 
+3: *WIPRAAGIRHEDMVPG 
+2: LVDPPGCRNSARGYGSW 
+1: T SGSPGLQEFGTRIWFL 
DNA: gcaagcccatgtgtgttgagagcttctcagactatccacctttgggtcgct 
+3: KPMCVESFSDYPPLGRF 
+2: QAHVC*ELLRLSTFGSL 
+1: A SPCVLRASQTIHLWVA 
DNA: ttgctgttcgtgatatgagacagacagttgcggtgggtgtcatcaaagcag 
+3: AVRDMRQTVAVGVIKAV 
+2: CCS*YETDSCGGCHQSS 
+1: L LFVI*DRQLRWVSSKQ 
DNA: tggacaagaaggctgctggagctggcaaggtcaccaagtctgcccagaaag 
+3: DKKAAGAGKVTKSAQKA 
+2: GQEGCWSWQGHQVCPES 
+1: W TRRLLELARSPSLPRK 
DNA: ctcagaaggctaaatgaatattatccctaatacctgccaccccactcttaa 
+3: QKAK*ILSLIPATPLLI 
+2: SEG*MNIIPNTCHPTLN 
+1: L RRLNEYYP*YLPPHS* 
DNA: tcagtggtggaagaacggtctcagaactgtttgtttcaattggccatttaa 
+3: SGGRTVSELFVSIGHLS 
+2: QWWKNGLRTVCFNWPFK 
+1: S VVEERSQNCLFQLAI* 
Figure 7. The frame of thcfos-l'usion protein is indicated in red (+I) and that of EEFlaj in blue (+3). Stop codons are 
indicated by asterisks. The highlighted sequence represents the cloning area composed of BgI II and Xba I sites. 
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2.4 Discussion 
The objective of work described in this chapter was to selectively enrich clones from a 
phage display fibroblast cDNA library that bound to autoantibodies from RA sera. 
Although no large increases of phage eluted at each round were seen, domination of one 
panning series by a clone encoding a known autoantigen in RA did occur. The discussion 
that follows focuses on the drawbacks of the methodology employed, ways these may be 
overcome and whether or not the findings described above can be considered a successful 
application of this phage display system. 
Z4.1 Clonal competition 
The great diversity of encoded inserts and displayed polypeptides in terms of size and 
sequence is the major difference between gene fragment libraries such as used in this 
work and the majority of phage display libraries successfully used for other applications. 
Random peptide libraries typically display a great diversity of peptides of small size, 
while in antibody fragment libraries variation is restricted to complimentarity- 
determining regions within a conserved structural framework. Such variation in encoded 
inserts may therefore be expected to have heterogeneous effects on phage particle 
assembly, infectivity and growth rates and rounds of amplification in liquid media may 
favour the growth and propagation of non-recombinant or other clones with a growth 
advantage. In one study using a gene fragment library phage particle yields were found 
to vary by I 00-fold between clones and in some cases by I O"-fold (Wilson et al., 1997). 
Other studies have resulted in successful enrichment despite such clonal competition 
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(Wilson et al., 1998) suggesting that these effects are often unpredictable and do not 
necessarily preclude a successful panning experiment. Some applications have attempted 
to limit this problem by performing only I or 2 rounds of affinity-enrichment and then 
attempting to identify binders by plaque lifts (Wilson et al., 1998). This strategy while 
reducing the number of clones needing to be screened to a few thousand, still suffers 
from some of the limitations mentioned earlier. We chose to perform no more than three 
rounds of affinity selection and analyse the population of phage obtained directly by 
sequencing. The domination of one panning series by a clone carrying a deletion of the 
fos gene is likely to represent an example of such clonal competition. In two series 
however a relatively diverse population was observed which may be enriched in antigen- 
encoding clones. 
Z4.2 Effects of a complex selecting ligand 
In contrast to much previous work using phage display libraries where selection was 
performed using a pure moiety, the selecting ligand used in this work was a complex 
mixture, representing the repertoire of IgG molecules found in patient sera. Again these 
will form a heterogeneous population in tenns of binding specificity, affinity and titre all 
of which will influence the degree of selection applied to individual phage clones and 
also the degree of enrichment seen. The cffects of these various factors on the dynamics 
of the selection process may mean that enrichment in terms of phage numbers during 
rounds of panning will not be seen but without precluding a successful selection. 
50 
Z4.3 Theprohlem of readingframe 
In a study exploring the feasibility of expressing prokaryotic genomic libraries using a 
phagemid system, a library composed of 100-700bp fragments of Staphylococcus aureus 
genomic DNA fragments was panned using human IgG and fibronectin (Jacobsson and 
Frykberg, 1995). Panned libraries were screened using oligonucleotide probes to known 
binding regions of Staphylococcal protein A and fibronectin-binding proteins in order to 
demonstrate enrichment which was confirmed, however interestingly all five fibronectin- 
binding clones isolated contained a +1 or -1 frameshift. In a related study, 47 out of 50 
binding clones possessed similar frameshifts. The implication is therefore that despite 
being out-offrame, a small amount of in-frame polypeptide is produced in the host 
bacteria because of ribosomal slippage and phage bearing these polypeptides are selected. 
Out-of-frame clones are likely to possess a survival advantage because they produce 
much lower levels of foreign protein. None of the coding sequences isolated from this 
library were in-frame including that of ETEF I alphal, suggesting that these 
considerations were likely to be important in this system. The implication for the work 
described is that an out-of-frame clone must not be discarded as a potential antigen. 
Z4.4 How may successful enrichment be monitored? 
The considerations discussed above and the differences from the best studied phage 
display applications impact upon an important practical problem encountered in the work 
described, that of how to judge the success of a panning experiment. Clearly monitoring 
eluted numbers of phage, which were initially relied upon may be unreliable. Direct 
binding assays of clones from panned libraries such as phage ELISA (Crameri and 
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Blaser, 1996), plaque lifts (Wilson et al., 1998) or dot blots (Barbas et al., 199 1) would 
not overcome the problem of reading frame. This is especially important, as many 
studies have demonstrated that binders may comprise a relatively small proportion even 
of a panned library. In the study of Ditzel and colleagues, I F(Ab) out of 25 screened 
bound the selecting substrate (Ditzel et al., 2000). In a recent publication from our 
laboratory employing the pJuFo system, one clone out of 30 sequenced encoded a 
fragment of a cell-surface receptor, which was subsequently demonstrated to be an 
autoantigen (Kemp et al., 2002). The only way to overcome these problems therefore 
may be to undertake relatively large-scale sequencing and follow up clones that appear to 
be interesting because of their sequence content. 
Z4.5 Successful cloning of an autoantigen or afurther example of clonal competition? 
A single clone encoding a fragment of EEF I alpha 1, a molecule recently demonstrated to 
be an autoantigen in Felty's syndrome as well as non-Felty's RA dominated one panning 
series. This did not occur in a parallel experiment performed in the absence of glycerol. 
It is of much interest that the objective of the study of Kjaer and colleagues (Kjaer et al., 
1998) was to isolate antibody fragments from a phage displayed antibody fragment 
library to this very same molecule, EEF I alphal and it was shown that binders could only 
be isolated in the presence of glycerol. This suggests that EEF I alpha I -antibody 
interactions may be glycerol-dependent in other contexts also and lends some support to 
the view that a selective enrichment was seen. No attempts to demonstrate direct binding 
of the clone to sera were made because the reading frame would prevent expression of 
significant levels of protein, however 5 of the pool of 20 RA sera used for panning were 
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confinned to contain antibodies to ETEF I alpha I by using a radiobinding assay, described 
in chapter 4. Although therefore this clone could have been enriched for non-specific 
reasons, we felt that this was likely to represent a genuine selective enrichment. 
Of note, the panning series performed with a pool of 10 established RA sera did not result 
in selection of this clone, although in fact a small but consistent differential in terms of 
numbers of phage eluted at each round was seen (table 4). Two coding sequences were 
represented amongst the relatively small number of clones sequenced. The differences 
observed between panning with different panels of sera may be due in part to differences 
in antibody titre although stochastic effects clearly may also occur. It is possible 
therefore that potentially antigenic clones are., over-represented in this series. 
2.4.6 Conclusions 
The work described in this chapter illustrates the differences between biopanning of 
gene-fragment libraries with IgG from human sera and previous well-studied applications 
of phage display. Evidence of clonal competition was observed, however the isolation of 
a clone encoding a known autoantigen in RA suggests that this can be overcome 
depending on the complexity of the starting libraries. No simple method for monitoring 
the success of a panning experiment was found because of the problem of even 
selectively enriched clones often being out-of-frame. On the basis of these observations a 
strategy for antigen discovery incorporating limited numbers of rounds of affinity 
enrichment followed by large-scale sequencing and detailed analysis of candidate 
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antigens was proposed. These considerations are applied to the screening of a phage- 
displayed library generated from human rheumatoid pannus described in chapter I 
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3 Construction and screening of a phage-displayed rheumatoid pannus 
cDNA library 
3.1 Introduction 
Disease-associated immune responses may be directed at either ubiquitous or organ- 
specific antigens. Many autoimmune diseases are characterised by both disease-specific 
and non-specific antibody production. The majority of even highly disease-specific 
autoantibodies, such as the myositis-specific anti-tRNA synthetase antibodies (Targoff, 
2000), are directed against ubiquitously expressed molecules and such antibodies are 
therefore believed to reflect unique aspects of the pathology in each case. In other 
situations such as Sjogren's syndrome disease-specific immune responses are directed at 
both ubiquitously expressed molecules such as SS-A/Ro and SS-B/La, and tissue specific 
antigens such as the M3 muscarinic receptor (Bacman et al., 1998) and ICA69 (Winer et 
al., 2002). Evidence from disease models suggests that there may be a hierarchy of 
antigens with responses to certain molecules being more relevant for disease progression 
(Winer et al., 2002). A number of antigens characterised in rheumatoid arthritis such as 
collagen II, hcgp 39, BiP and possibly citrullinated antigens (Baeten et al., 2001) are 
preferentially expressed in inflamed joints. It is possible therefore that by using libraries 
derived from the site of inflammation antigens more relevant to disease pathogenesis or 
progression may be isolated. 
Successful screening of a library derived from rheumatoid synovial membrane has been 
undertaken by only one group yielding the antigens follistatin-related protein (FRP) and 
gp- 130 RAPS (Tanaka et al., 2000; Tanaka et al., 1998), however a relatively small 
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number of primary recombinants (150 000) were obtained. We sought therefore to 
generate a more diverse library from primary human RA tissue and express it on the 
surface of filamentous phage in order to allow screening using the selective enriclunent 
procedures described previously in chapter 2. 
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3.2 Materials and methods 
3. ZI Construction of a cDNA library in A TriplEx 2 (BD Clontech) from rheumatoid 
pannus 
Initial attempts to synthesise and clone cDNA using the UNIZAPTM series of lambda 
vectors (Stratagene, La Jolla, CA) were unsuccessful, so the library described below was 
generated using the SMARTTm cDNA Library Construction Kit (Clontech, Palo Alto, 
CA). 
3.2.1.1 Extraction andpurification ofmessenger RNA 
Tissue was obtained from a 64-year-old subject with longstanding rheumatoid arthritis 
undergoing a total hip replacement. Tissue obtained at surgery was immediately snap- 
frozen and stored in liquid nitrogen. Light microscopy and haernatoxylin and eosin 
staining confirmed the presence of a typical inflammatory infiltrate. Total RNA was 
extracted using TRIZOLTm (Invitrogen, Paisley, UK) and mRNA purified using oligo(dT) 
cellulose (FastTrack@ 2.0, Invitrogen). Briefly approximately Ig frozen tissue was 
homogenised in a pestle and mortar cooled with liquid nitrogen until a fine powder was 
obtained. The homogenate was added to 20ml of TRIZOLTm reagent and mixed 
thoroughly to permit complete dissociation of nucleoprotein complexes. Two millilitres 
of chlorofonn was added to precipitate protein and DNA, and after separation of aqueous 
and organic phases the aqueous phase was precipitated with 0.8 volume 100% 
isopropanol. The pellet of total RNA was resuspended in I OOW of RNAse free water and 
added to I Oml FastTrack@ 2.0 lysis buffer (200mM NaCl, 200mM Tris pH 7.5,1.5 mM 
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MgC12,2% SDS and proprietary RNAse-protein degrader), incubated at 65'C for 5 
minutes and then chilled on ice for I minute. The tube was then placed at room 
temperature and 5M NaCI added to a final concentration of 500mM. At this point the 
lysate was incubated with 75mg of oligo(dT) cellulose for 60 minutes at room 
temperature. The beads were then washed first with binding buffer (500m. M NaCl, 
I OmM Tris-Cl pH 7.5) followed by low salt wash buffer (25OmM NaCl, I OmM Tris-Cl 
pH 7.5). The bound mRNA was eluted with I OmM Tris-Cl pH 7.5, precipitated with 
ethanol and finally resuspended in lOmM Tris-Cl pH 7.5. Quality and quantity of the 
mRNA obtained was assessed by agarose gel electrophoresis. A yield of approximately 
30gg of poly (A) mRNA was obtained from Ig of tissue. 
3.2.1.2 cDNA synthesis and cloning 
A PCR-based protocol as supplied by the manufacturer was followed. The principle of 
the SMART method is outlined in figure 8. Approximately O. Sgg of poly(A) mRNA was 
used as template for first strand synthesis. The following protocol was followed (from 
manufacturer's instructions): 
Component Volume (gl) 
RNA I 
SMART III oligo (I OgM) I 
Modified oligo d(T) primer (10pM) I 
11,0 2 
Total 5 
Heat to 70*C, chill on ice 
Then add: 
5x I' strand buffer 2 
DTr (20mM) I 
dNTP mix (I OmM each) I 
SuperScriptTmIIRT I 
Total 10 
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Figure 8. The SMART' method for cDNA synthesis 
Poly(A) mRNA 
poly(A) 3' 
modified oligo(dT) primer 
SMART'" oligo 
2 ggg 5' 
Poly(A) mRNA 
poly(A) 31 
CCC 
Nascent Is'strand of cDNA 
Adaptor sequence 
Complete I' strand 
Adaptor sequence 
3' ccc 0 S' 
5' PCR primer 3' PCR primer 
Complete cDNA 
Figure 8. (1,2). First strand of* cDNA is synthesised by MMLV rcvcrsc-transcriptase frorn the mRNA template and a 
modified oligo(dT) primer containing an anchor sequence. An oligo(C) tract is added at the 3' end of the nascent first 
strand due to the intrinsic terminal translerasc activity oi'MMLV-RT to which the SMART" oligonucleotide hybridiscs 
providing an extended template i'Or the RT enzyme. (3) Thus a first strand cDNA molecule with unique adaptor sequences 
at each end is generated and amplified by PCR. Sfi I sites in the adaptors allow restriction and cloning. (figure adapledfrom 
manufacturer's information) 
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The reaction was incubated at 42"C for one hour. Two microlitres of the first-strand 
reaction were subsequently used as template for PCR using the Advantage 2 PCR kit 
(Clontech). Fifteen cycles of PCR were used. Agarose gel analysis of 5gl of a 100gl 
reaction is shown in figure 9. 
Polymerases were removed from the reaction by digestion with proteinase K and the 
cDNA restricted with Sfl 1. The digested cDNA was then size-fractionated using a 
Sepharose CL-2B column, fractions containing cDNA from 500 to 2000bp in size were 
pooled and precipitated. The cDNA was quantitated by agarose gel analysis and ligated 
to pre-digested and phosphatased X triplex2. Ligations were packaged using GigapackTm 
III Gold packaging extract (Stratagene) and final libraries titred with fresh XL- I Blue 
MRF' host cells. Libraries were amplified on solid media according to standard methods 
(Sambrook et al., 1989) and final libraries stored in 7% DMSO at -80'C. 
3.2.1.3 Titre and composition ofthe A triplex2 pannus library 
Approximately 3x 10' primary recombinants were obtained with less than 10% non- 
recombinance as assessed by blue-white screening. Size distribution of inserts from the 
amplified library was assessed by PCR analysis using primers flanking the cloning site 
(figure 10). 
60 
Figure 9. SMART PCR product prior to cloning. 
2322bp 
2027bp 
564bp 
Figure 9. A smear of cDNA can be seen extending from below 500bp to around 2000bp in size. Some prominent bands 
corresponding to particularly frequent mRNAs can also be seen. 
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Figure 10. PCR analysis of inserts from I TriplEx2 pannus library 
1353bp 
872bp 
603bp 
1353bp 
872bp 
603bp 
Mgure 10. The majority of inserts were sized between approximately 600 and I 100bp (allowing for approximately 2(X)bp 
of vector sequence in each PCR product). Five of the 40 inserts (12.5%) were above 1353 bp in size. 
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Composition of the library was also assessed by hybridization with a 1207bp P actin 
cDNA probe beginning 276bp from the 5' end of the mRNA transcript (total length 
1761bp). Fifty-two positive plaques were identified out of approximately 50,000 pfii 
screened giving a frequency of 0.1%, therefore the library was considered to be 
representative. 
3. Z2 Screening of thel TriplEx2pannus library 
Approximately 50,000 pfu of the pannus library were plated per 21 Omm. dish (Nunc) on 
NZY agar using standard methodology. Plaque lifts were performed onto supported 
nitrocellulose (HybondTm C Extra, Arnersharn Pharmacia Biotech, Bucks., UK) and 
washed in PBS/tween 0.5% for 30 minutes to remove all traces of top agar. Membranes 
were then blocked for 1 hour at room temperature with 5% skimmed milk in PBS/tween 
0.5% and rinsed briefly. A 1150 dilution of a pool of 10 early RA sera, which had been 
preadsorbed with E. Coli lysate, was then allowed to react with the filters for 2 hours at 
room temperature. After four washes in PBS/tween 0.5% bound IgG was detected with 
alkaline phosphatase-conjugated goat anti-human IgG (Sigma). 
3. Z3 Generation of the phage-displayedpannus cDNA library 
Thek TriplEx2 multiple cloning site and any insert lies within a plasmid incorporated in 
the lambda vector. The junction of plasmid and lambda arms is flanked by IoxP sites, 
hence transduction of phage into a Cre-recombinase positive strain of E. Coli such as 
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BM25.8 and growth at 30'C results in release and circularisation of the pTriplEx2 
plasmid, which can then be isolated and propagated in any convenient host (figure 11). 
Such in-vivo excision of the pannus X TriplEx2 library en masse was performed by 
infection of a culture of BM25.8 with 1012 pfa of library followed by subsequent isolation 
of "maxi-prep" plasmid DNA. Restriction with SJH released inserts and those in the size 
range above approximately 600bp were gel-purified and ligated to Sfi I-digested and 
phosphatased pJuFo. Ligations were used to transform high-efficiency electrocompetent 
XL- I blue MRF' cells and approximately 2x 10' transformants obtained. Recombinance 
and approximate average insert size was assessed by PCR analysis using flanking primers 
revealing a similar distribution of insert sizes as the original library (figure 12). The 
transformed host cells were converted into the final phage particle library by infection 
with VCS M 13 helper phage at a multiplicity of infection of approximately 20: 1 and 
overnight growth in a 100ml culture containing tetracycline, ampicillin and kanamycin as 
described previously. The culture was clarified of bacterial debris and phage particles 
collected by PEG/salt precipitation. Five millilitres of final library was obtained with a 
titre of 10 cfu/ml. 
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Figure 11. In-vivo excision of the plasmid pTripIEx2 
1313C 
pUC on 
Amp' 
lacz, 
on 
Ioxp 
t 
left arm insert X right arm 
I 
IOXP Ioxp 
t7 Site-specific recombination 
in Cre-expressing strain at 
homologous IoxP sites 
leads to "looping out" of 
the pTriplEx2 plasmid 
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Figure 12. PCR analysis of clones from the pjuFo pannus library 
1500bp - 
1000bp 
500bp 
1500bp - 
1000bp 
500bp, 
Figure 12. The majority of clones contain an insert of >1000bp. One insert below 500bp is seen and one probable 
nonrecombinant is seen (*) 
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3. Z4 Screening of the phage-displayedpannus library by selective enrichment 
Dynabeads@ Protein A (Dynal@ Biotech, Oslo, Norway) were used as the solid substrate 
for the selective enrichment procedures described below. One hundred microlitres of 
Dynabeads Protein A has a theoretical binding capacity for human IgG of 25gg 
(manufacturer's information) as compared to approximately I gg for passive adsorption to 
a single well of a microtitre, plate (based on manufacturer's information for Costar 3590 
high-binding polystyrene 96 well EIA/RIA plates). Hence a much larger number of IgG 
molecules would be available for binding to phage-displayed. ligands. In addition capture 
of IgG molecules via their Fc regions may prevent loss of binding specificity as a result 
of the denaturation inherent in passive adsorption to solid surfaces (Butler et al., 1993). 
Dynabeads Protein A (I 00[il) were washed in PB S-tween(PB St) and blocked by 
incubation with 5% skimmed milk (SM) solution in PBSt for I hour at 4'C. The blocking 
solution was removed and the Dynabeads reacted with a I/ 10 dilution of a serum pool 
composed of 20 patients with early RA (within 6 months of onset of symptoms) 
containing approximately I OOgg of IgG in total. The IgG-coated Dynabeads were then 
allowed to bind to 1010 pfu of the phage-displayed library ( pre-incubated with 10% 
normal human serum in 5%SM/PBSt) overnight at 4'C. After 6 washes with PBSt, 
bound phage were eluted, neutralised and amplified as previously described. After three 
rounds of panning the diversity of the phage population was established by PCR analysis 
and sequencing of 40 clones. 
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3.3 Results 
Polymerase chain reaction analysis of 40 clones from the third round of selective 
enrichment revealed a diversity of inserts ranging from approximately 700 to 1500bp in 
size. Five clones generated a very small PCR product corresponding to amplification 
from vector alone and 3 clones did not amplify at all suggesting a deletion of thefos gene 
as encountered previously. The remaining 30 clones were sequenced using a sense 
primer located in thefos gene 134 bp upstream of the cloning site. Identities were 
established by comparison with DNA sequences deposited in the GENBANK, EMBL 
and DDBJ databases by BLAST analysis (Altschul et al., 1997). Nineteen clones 
contained sequences from known genes (summarised in table 6) and 11 clones 
represented uncharacterised sequences including one for which no database match was 
found (summarised in table 7). A more detailed analysis of these sequences is presented 
in the following sections. Sequence alignments were generated using the EMBOSS 
program (European Bioinformatics Institute, http: //www. ebi. ac. uk/emboss/aligrv) and 
translations perfonned using the Baylor College of Medicine Sequence Utilities 
(http: //searchlauncher. bcm. tmc. edu/seq-util/seq-util. htrnl). 
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3.3.1 Clones encoding known genes. 
Table 6. Clones isolated from panning of a phage-displayed pannus cDNA library 
encoding known genes. 
Identity Approximate size 
(BP) 
Number of 
clones 
Accession of primary 
match 
Sequence content 
(coding or UTR) 
Ig fragments 700-1000 13 Various CDS 
NOLA3 700 3 NMO18648 Full lengdi including 
(snoRNP) 5'UTR 
Mitochondrial 700 1 AF382012 CDS 
NADH subunit 2 
NPL4 900 1 NMO17921 3'UTR 
(ribosomal protein) 
WNTIOB 800 1 HSU81787 3'UTR 
3.3.1.1 Immunoglobulin genefragments 
Thirteen of the 30 clones sequenced encoded'a variety of immunoglobulin fragments. All 
were light chains and all clones contained coding sequence in addition to 3' untranslated 
regions. Several explanations for this finding may be proposed. The most likely is that 
these clones were selected because of direct binding of expressed Ig fragments to free 
Protein A on the selecting substrate. Although the beads were incubated with an excess 
of human serum during the coating step, some binding sites will inevitably be empty and 
the great affinity of protein A for Ig may have led to selective enrichment. An alternative 
explanation is that these clones were selected by IgG rheumatoid factors in the patient 
sera. It is also possible that the original library contained such a high frequency of Ig 
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fragments. However as these clones were not felt to be relevant to the overall aims of the 
procedure they were not characterised in any more detail. 
3.3.1.2 The small nucleolar ribonuclearprotein NOLA3 
Three of the 30 clones sequenced encoded an identical insert comprising almost the entire 
NOLA3 gene including part of the 5' untranslated region. Sequence aligmnent of clone 
pJuFo/NOL43 and mRNA sequence NNt-O 18648 is shown in figure 13 and the reading 
frame of this clone in figure 14. As can be seen from the figure 9,70bp of the 3' 
untranslated region is included in this clone, which contains 2 stop codons (figure 10). Is 
it possible therefore that this protein will be displayed on the surface of the phage and be 
available potentially to bind to antibodies? The reading frame attached to thefos frame 
(shown in blue in figure 14) is in fact different from that of the NOLA3, however as 
discussed previously in chapter 2 such frameshifts are not uncommon in phage display 
systems and do not preclude the generation of small numbers of phage particles which 
express the cognate polypeptide. In addition antibodies against ribonuclear proteins have 
been characterised in a number of disease states. For these reasons attempts were made 
to demonstrate antibodies to NOLA3. The NOL, 43 coding sequence was amplified by 
PCR and cloned into the plasmid pcDNA3 in order generate "S labelled protein for 
immunoprecipitation studies, however expression was unsuccessful and therefore it was 
not possible to establish whether or not this molecule represents a target of antibodies in 
RA. 
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Figure 13. Sequence alignment of pjuFo NOLA3 clone. 
piuro/NOLA3 
NOLA3 (NN018648) 
101 GCAGATCTTCTAGAGGCCJk! rTJL! rGGCCC-GGGGCGGTCGGGCGGACCACTG 150 
1 ggccacgaggggaaattgacgaacaccjtgacgcgcjtcgggcggaccactg so 
151 CAGACTGAGCGGTGGACCGAATTGGGACCGCTGGCTTATAAGCGATCATG 200 
51 cagactgagcggtggaccgaattgggaccgctggcttataagcgatcatg 100 
m 
201 TTTCTCCAGTATTACCTCAACGAGCAGGGAGATCGAGTCTATACGCTGAA 250 
101 tttctccagtattacctcaacgagcagggagatcgagtctatacgctgaa 150 
FLQYYLNE9GDRVYTLK 
251 GAAATTTGACCCGATGCr. ACAACAGACCTGCTCAGCCCATCCTGCTCGGT 300 
151 gaaatttgacccgatgggacaacagacctgctcagcccatcctgctcggt 200 
KFDPMGQQTCSAHPARF 
301 TCTCCCCAGATGACAAATACTCTCGACACCGAATCACCATCAAGAAACGC 350 
201 tctccccagatgacaaatactctcgacaccgaatcaccatcaagaaacgc 250 
SPDDKYSRHRITIKKR 
351 TTCAAGGTGCTCATGACCCAGCAACCGCGCCCTGTCCTCTGAGGGTCCCT 400 
251 ttcaaggtgctcatgacccagcaaccgcgccctgtcctctgagggtccct 300 
FKVLMTQQPRPVL* 
401 TAAACTGATGTCTTTTCTGCCACCTGTTACCCCTCGGAGACTCCGTAACC 450 
301 taaactgatgtcttttctgccacctgttacccctcggagactcccjtaacc 350 
451 AAACTCTTTGGACTGTGAGCCCTGATGCCTTTTTGCCAGCCATACTCTTT 500 
351 aaactcttcggactgtgagccctgatgcctttttgccagccatactcttt 400 
501 GGCATCCAGTCTCTCGTGGCGATTGATTATGCTTGTGTGANGCAATCATG 550 
401 ggcatccagtctctcgtggcgattgattatgcttgtgtgaggcaatcatg 450 
Figure 13. Nucleotidc sequence alignment is shown in black and the translated protein sequence in red. The gold shaded 
sequence represents the Sfi I cloning site of the vector. 
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Figure 14. Reading frame of pjuFo NOLA3 clone 
DNA: AGATCTTCTAGAGGCCATTATGWCGGGGGCGGTCGGGCGGACCACTGCAG 
+3: 1F*RPLWPGAVGRTTAD 
+2: DLLEAIMAGGGRADHCR 
+1: R SSRGHYGRGRSGGPLQ 
DNA: ACTGAGCGGTGGACCGAATTGGGACCGCTGGCTT GCGATCATGTTTC 
+3: *AVDRIGTAGL 
AfMA 
IMFL 
+2: LSGGPNWDRWLISDHVS 
+1: T ERWTELGPLAYKRSCF 
DNA: TCCAGTATTACCTCAACGAGCAGGGAGATCGAGTCTATACGCTGAAGAAAT 
+3: QYYLNEQGDRVYTLKKF 
+2: PVLPQRAGRSSLYAEEI 
+1: S SITSTSREIESIR*RN 
DNA: TTGACCCGATGGGACAACAGACCTGCTCAGCCCATCCTGCTCGGTTCTCCC 
+3: DPMGQQTCSAHPARFSP 
+2: *PDGTTDLLSPSCSVLP 
+1: L TRWDNRPAQPILLGSP 
DNA: CAGATGACAAATACTCTCGACACCGAATCACCATCAAGAAACGCTTCAAGG 
+3: DDKYSRHRITIKKRFKV 
+2: RQILSTPNHHQETLQG 
+1: Q MTNTLDTESPSRNASR 
DNA: TGCTCATGACCCAGCAACCGCGCCCTGTCCTCTGAGGGTCCCTTAAACTGA 
+3: LMTQQPRPVL*GSLXLM 
+2: AHDPATAPCPLRVP*TD 
+1: c s*PSNRALSSEGPLN* 
DNA: TGTCTTTTCTGCCACCTGTTACCCCTCGGAGACTCCGTAACCAAACTCTTT 
+3: SFLPPVTPRRLRNQTLW 
+2: VFSATCYPSETP*PNSL 
+1: C LFCHLLPLGDSVTKLF 
DNA: GGACTGTGAGCCCTGATGCCTTTTTGCCAGCCATACTCTTTGGCATCCAGT 
+3: TVSPDAFLPAILFGIQS 
+2: DCEP*CLFASHTLWHPV 
+1: G L*ALMPFCQPYSLASS 
DNA: CTCTCGTGGCGATTGATTATGCTTGTGTGANGCAATCATCGTGGCATCCCC 
+3: LVAIDYACVXQSWWHPH 
+2: SRGD*LCLCXAIMVASP 
+I: L SWRLIMLV*XNHGGIP 
Figure 14. The reading frame attached to thefos protein is shown in blue and the correct NOLA3 frame in red. The TAA 
stop codon highlighted in green will be ignored as the XLI Blue MRF cells used as host bacteria are supE and therefore 
suppress amber stop codons. The cloning site of pJuFo is highlighted in gold. 
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3.3.1.3 Mitochondrial NADH subunit 2 
One clone of the 30 sequenced encoded the c-terminal 209 amino acids and 3' 
untranslated region of subunit 2 of the mitochondrial enzyme NAD dehydrogenase 
(ND2). Sequence aligmnent is shown in figure 1 S. Although not truly enriched the 
presence of this clone was nevertheless of interest. Occasional reports of anti- 
mitochondrial reactivity in patients with rheumatoid arthritis do exist (refs). However 
more specifically a monoclonal antibody produced by aB cell hybridoma generated from 
rheumatoid synovium has been shown to possess strong anti-mitochondrial activity and 
stain 38- and 50-kDa bands in mitochondrial extracts (Krenn et al., 1998). NADH2 is a 
38kDa protein and it is therefore possible that NADH2 is the target of this antibody. One 
problem however concerns the expression of this protein in bacteria. NADH2 is encoded 
by the mitochondrial genome and therefore TGA codons are read as W and not a stop as 
in eukaryotic or bacterial cells. The clone shown in figure 15 contains 4 such in-frame 
TGA codons (highlighted in green) and therefore even allowing for ribosomal slippage it 
seems unlikely that this polypeptide would be expressed in its entirety in the bacterial 
host cells or on the surface of phage particles used in the screening procedures. It is 
possible that partial expression is sufficient to display some determinants critical for 
binding however. 
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Figure 15. Sequence alignment of pjuFo/ND2 
33 CGCGCTGCAAACCGAAATCGCGAACCTGCTGAAAGAAAAAGAAAAGCTGG 82 
399 aaaactaggaatagccccctttcacttctgagtcccagaggttacccaag 448 
83 AGTTCATCCTGGCGGCACACGGTGGTTGCAGATCTTCTAGAGGCCATTAT 138 
449 gcacccctctgacatccggcctgcttcttctcacatgacaaaaactagcc 498 
pJUFOIND2 139 GGCCGGGCAATCATATACCAAATCTCTCCCTCACTAAACGNAAGCCTTCT 182 
ND2(AF382012) 499 cccatctcaatcatataccaaatctctccctcactaaacgtaagccttct 548 
ISIMYQISPSLNVSLL 
183 CCTCACTCTCTCAATCTTATCCATCATAGCAGGCAGTI W GTGGATTAA 232 
549 cctcactctctcaatcttatccatcatagcaggcagt M ggtggattaa 598 
LTLSILSIMAGSWGGLN 
233 ACCAAACCCAGCTACGCAAAACCTTAGCATACTCCTCAATTACCCACATA 282 
599 accaaacccagctacgcaaaatcttagcatactcctcaattacccacata 648 
QTQLRKILAYSSITHM 
283 GGAJIWTAATAGCAGTTCTACCGTACAACCCTAACATAACCATTCTTAA 332 
649 gga M ataatagcagttctaccgtacaaccctaacataaccattcttaa 698 
GWMMAVLPYNPNMTILN 
333 TTTAACTATTTATATTATCCTAACTACTACCGCATTCCTACTACTCAACT 382 
699 tttaactatttatattatcctaactactaccgcattcctactactcaact 748 
LTIYIILTTTAFLLLNL 
383 TAAACTCCAGCACCACGACCCTACTACTATCTCGCACCIIIIAACAAGCTA 432 
749 taaactccagcaccacgaccctactactatctcgcacC M aacaagcta 797 
NSSTTTLLLSRTWNKL 
433 ACAIWTAACACCCTTAATTCCATCCACCCTCCTCTCCCTAGGAGGCCT 482 
798 aca M ctaacacccttaattccatccaccctcctctccctaggaggcct 847 
TWLTPLIPSTLLSLGGL 
483 GCCCCCGCTAACCGGCTTTTTGCCCAAATGGGNCATTATCGAAGAATTCA 532 
848 gcccccgctaaccggctttttgcccaaatgggccattatcgaagaattca 897 
PPLTGFLPKWAIIEEFT 
533 CAAAAAACAATAACCTCATCATCCCCACCATCATAGCCACCATCACCCTC 582 
898 caaaaaacaatagcctcatcatccccaccatcatagccaccatcaccctc 945 
KNNSLIIPTIMATITL 
583 CTTAACCTCTACTTCTACCTACGGCTAATCTACTCCACCTCAATTACACT 632 
946 cttaacctctacttctacctacgcctaatctactccacctcaatcacact 995 
LNLYFYLRLIYSTSTTL 
633 ACTCCCCATATCT-ACAACGTAA ---- AAAANAANANNTTNNNANNN 677 
996 actccccatatctaacaacgtaaaaataaaatgacagtttgaacata 1045 
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3.3.2 Clones encoding uncharacterised sequences 
Eleven clones carried uncharacterised sequences (table 7). Databases matches were 
found for all but one sequence, and EST matches for all except 2 sequences suggesting 
that the majority represent genuine mRNA transcripts and not PCR artefacts from 
contaminating DNA for instance. All sequences were screened for the presence of 
potential open reading ftames using the BCM sequence utilities program. In four of the 
sequences shown, multiple stop codons were found in all three reading frames. Possible 
reading frames comprising at least 100 amino acids were found in the remaining four 
sequences however whether these sequences represent polypeptide fragment of 
uncharacterised genes or non-translated sequence is unclear as none demonstrated any 
homology to known genes. 
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Table 7. Clones isolated from a pannus library encoding uncharacterised sequences 
Identity Approximate Number Accession of EST matches Open Putative conserved 
size (BP) of clones primary match reading domains or 
frame homologies to known 
proteins 
Chromosome 12 1500 2 AC026786.5 D44811 Possible No 
unidentified BE315280 (Alu repeats) 
sequence BU189827 
BU625379 
Chromosome 12 900 2 AC012150 Numerous No No 
BAC clone e. g. 
BG341239 
Chromosome 19 900 1 AC010328 Numerous No No 
unidentified e. g. (Alu repeats) 
sequence BQ938400 
Chromosome 1 900 1 AL354721 None Possible No 
unidentified (Alu repeats) 
sequence 
Chromosome 19 1000 1 AC007201 Numerous Possible No 
unidentified e. g. 
sequence BG397564 
Chromosome 2 1000 1 AC012670 Partial e. g. No No 
unidcntifed AA582690 
sequence from 
BAC clone RP II- 
514A9 
Chromosome 9 1000 1 AL359997 None No No 
unidentified 
sequence from 
clone RP II- 
71A24 
Chromosome 5 1100 1 ACI 13358 N57826 Possible No 
unidentified 
sequence from 
clone CTD- 
3075M2 
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3.4 Discussion 
The work described above represents attempts made to isolate novel antigens by the 
construction and screening of a phage-displayed pannus cDNA library with IgG from 
patients with early rheumatoid arthritis. A library was generated using a PCR-based 
method and screened with IgG immobilised on Dynabeads Protein A. The majority of 
the clones recovered were Ig fragments probably because of selection applied by free 
Protein A on the selecting substrate. Of the remainder, 2 candidate antigens were 
identified and also a number of uncharacterised sequences isolated most of which are 
likely to represent background. Factors that are likely to impact on the success of this 
approach are discussed below. 
3.4.1 Library construction 
The SMART TM method was chosen for the library construction as availability of poly(A) 
mRNA was limiting. However there are several reasons why such libraries may not be 
ideally suited to immunoscreening by any method. The method relies on the addition of 
an oligo(dC) tract to the end of first strand cDNAs to which the SMART oligonucleotide 
then hydridises. This oligo(dC) tract is not added if the reverse transcriptase enzyme 
terminates prematurely and therefore the system is designed to preferentially amplify 
full-length mRNAs including 5' UTRs which often include stop codons (as seen in the 
NOLA3 clone, figure 13). Therefore some cDNAs will not be expressed as polypeptides 
on the surface of phage particles. Clearly this assumes that all mRNAs are intact as 
otherwise premature termination will take place, this is likely to be responsible for the 
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generation of truncated mRNAs as in the pJuFu/ND2 clone. In addition first strand 
synthesis occurs from a modified oligo(dT) primer and hence the library will be biased 
towards 3' ends of genes. This is manifest in the isolated sequences as the presence of 
3'UTRs of genes and C-termini. A random primed library would include a greater 
diversity of sequences including N-termini and would be a better "antigen library" to 
screen. However particularly when poly(A) mRNA is limiting this is technically much 
more difficult and therefore was not attempted in this case. 
3.4.2 Methods usedfor screening 
DynabeadsTm Protein A were used to capture IgG directly from serum samples as this 
method is theoretically least likely to lead to loss of binding specificity as a result of ' 
denaturation. This method also has the advantage that IgG purification is not required. 
However it is possible that serum proteins may adsorb onto the magnetic particles leading 
to the enrichment of serum-binding factors, and also the domination by immunoglobulin 
fragment-expressing clones is apparent and has been encountered by others (P. F. Watson, 
personal communication). An alternative methodology is the biotinylation of purified 
IgG from patients and immobilisation on DynabeadSTM Streptavidin M-280; however 
biotinylation itself may also lead to some denaturation of binding sites. 
Autoantibodies as yet undiscovered in rheumatoid arthritis may be of low affinity, low 
titre and be directed at molecules expressed at low levels in cells and tissues. To 
maximise the chance of detecting a lower affinity interaction all incubations were 
performed at 4'C in order to slow down the dissociation of low affinity interactions. 
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However screening was perfonned by reacting the phage library with beads, which had 
been pre-coated with IgG. It is possible that reacting the phage with IgG directly in 
solution might allow multivalent immune complexes to form and capture of these on an 
affinity matrix may be a more efficient method of detecting rare phage-antibody 
interactions. Recent work describing the cloning of tumour antigens from a phage- 
displayed cDNA library from colon cancers provides some evidence that such approaches 
may be more successful (Somers et al., 2002). 
3.4.3 Methodsforjudging successful enrichment of antigens 
As discussed in the previous chapter, great difficulties are encountered when attempting 
to judge the success of an enrichment experiment using this system. Titration of phage 
numbers eluted at each round was not performed but a larger number of clones were 
sequenced than in the experiments described in chapter 2, and it is clear that some clones 
were enriched. Whether this was because of binding to selecting antibody or for other 
reasons is unclear. Of the 2 coding sequences isolated, specific problems prevented the 
use of immunoprecipitation assays and therefore attempts to search for antibodies to 
either of these molecules will require further work. Subcloning, expression and 
purification of the NOLA3 product would allow Western blotting and ELISA studies. 
The mitochondrial gcnc NADH2 presents a more difficult problem. Because of 
mitochondrial codon usage it was not possible to express the cDNA in bacteria or 
eukaryotic cells directly, and protein purified from cells or tissues would need to be 
obtained for specific binding studies. Western blotting using microsomal preparations 
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may give some information on whether sera bound a protein of the relevant size and 
combined with MALDITOF mass spectrometry may allow identification. 
3.4.4 Conclusions 
Although many methodological problems remain unsolved, the work described above 
demonstrates the feasibility of constructing both lambda and phage-displayed. cDNA 
libraries from human rheumatoid synovium. A valuable resource has been established 
which may be useful not only for the study of antigens but also for the isolation of orphan 
receptors and ligands important in other aspects of the biology of inflammatory diseases. 
Further work is required in order to establish whether or not the molecules highlighted 
above are the targets of autoantibodies in rheumatoid arthritis. 
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4 Autoantibodies to eukaryotie translation elongation factor 1-CC 1 
(eEFIa) in rheumatoid arthritis and other systemic diseases. 
4.1 Introduction 
4.1.1 Eukaryotic translation elongationfactor ]-alpha I(eEF1q) 
Eukaryotic translation elongation factor I -alpha I is known to form a complex with both 
GDP or GTP and aminoacyl-tRNA promoting its binding to 80s ribosomes (Negrutskii 
and El'skaya, 1998). Although its physiological function is not known it is believed 
therefore to play a role in tRNA and aminoacyl-tRNA channelling in eukaryotic cells. 
Antibodies to eEF Ia (anti-eEF I a) have been reported only twice previously - in 66% of 
patients with Felty's syndrome (Ditzel et al., 2000) and 20% of Japanese patients with 
atopic dennatitis (Ohkouchi et al., 1999). Although a role in the pathogenesis of the 
neutropaenia of Felty's syndrome was suggested, antibodies were also found in 4/21 non- 
Felty's RA patients and 1/16 SLE patients tested (Ditzel et al., 2000). Felty's syndrome 
is known to be strongly associated with HLA DRB 1 *0401 (Weyand et al., 1995) and it is 
therefore possible that the primary association of this antibody is with HLA genotype and 
not neutropaenia, although no analysis of HLA types was perfonned. In addition Felty's 
syndrome is associated with severe, erosive disease and other extra-articular features such 
as vasculitis and it is possible therefore that the primary association of anti- eEF I (x is 
with anyone of these phenotypes. Anti- eEFla could therefore bean important 
diagnostic or prognostic marker in rheumatoid arthritis and other diseases. 
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4. L2 Anti-eEFIa and anti-nuclear and anti-neutrophil cytoplasmic antibodies. 
The presence of antibodies to eEF Ia in Felty's syndrome correlates with anti-nuclear 
antibody (ANA) positivity, both nuclear and cytoplasmic staining is seen (Ditzel et al., 
2000); this is somewhat unexpected as eEF Ia is believed to have a role in correct codon- 
anticodon selection in the ribosome and therefore predominantly cytoplasmic staining 
would be expected. In addition staining of neutrophil nuclei was seen but not of 
lymphocyte nuclei implying a cell specificity. That the nuclear staining is due to anti- 
eEF I (x and not another specificity is supported by the binding pattern of a cloned anti- 
eEF Ia F(ab) fragment (Ditzel et al., 2000). The basis of these observations has not been 
well established. Anti-nuclear antibodies (Nishimura et al., 1996) (ANA) and anti- 
neutrophil cytoplasmic antibodies (Mustila et al., 2000) (ANCA) of unknown specificity 
have been reported in up to 35% and 50% of patients with rheumatoid arthritis and 
therefore it is possible that anti-eEF I cc accounts for a proportion of these. As these tests 
are in routine clinical use an important aspect of the investigation of anti-eEF I (x would 
be to cstabl ish to what extent anti-eEF I cc accounts for anti-nuclear and anti-cytoplasmic 
staining patterns. Additionally it would be of importance to establish the frequency of 
anti-eEF I ot in other disease states characterised by positive ANA such as SLE and other 
conncctivc tissuc diseascs. 
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4. L3Anti-eEFla andneutropaenia 
The association of anti-eEF I (x with neutropaenia is also of interest. During neutrophil 
apoptosis induced in-vitro, apoptotic bodies containing high levels of eEF Ia have been 
observed at the cell surface (Ditzel et al., 2000) suggesting that at this time the antigen 
may be accessible to extracellular antibody and the possibility of antibody-dependent 
pathogenicity. Alternatively destruction of neutrophils by splenic macrophages may 
result in the presentation of previously sequestered eEF I oc and the generation of 
antibodies. Whatever the mechanism, anti-cEF Ia could potentially represent a novel 
marker for autoimmune neutropaenia and allow differentiation from other causes of 
neutropaenia such as drug-induced bone marrow suppression, a common clinical 
problem. Up to 50% of patients with SLE have mild neutropaenia and an association 
with anti-Ro antibodies has been demonstrated (Kurien et al., 2000; Nossent and Swaak, 
199 1), however only 20% of patients are anti-Ro positive (Kurien et al., 2000) hence it is 
possible that other autoantibodies may play a role in pathogenesis. It is therefore 
interesting that in the study of Ohkouchi et al (Ohkouchi et al., 1999), anti-eEF I cc 
positive patients were found to have lower white cell counts and a higher incidence of 
facial dermatitis; the authors have suggested that this subgroup of patients may have a 
lupus-like disease. 
Interest in anti-eEFIcc initially stemmed from its isolation during the selective 
enrichment experiments described in chapter 2, however on the basis of the work 
discussed above we suggest that these antibodies may define a subgroup of patients with 
RA, have other important disease associations or shed light on pathophysiology. The 
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presence of anti-eEF I (x has only to date been evaluated in 21 patients with non-Felty's 
RA and 15 patients with SLE. In order to begin addressing these questions we have 
established a radioimmunoprecipitation assay for anti-eEF I cc and used this assay to 
compare the frequency of anti-eEF I cc in panels of sera from patients with established and 
early RA, SLE, systemic sclerosis, polymyositis and Graves' disease. 
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4.2 Methods 
4. Zl Construction of theplasmidpcDNA31efa 
The eEF I cc open reading frame was obtained by PCR from IMAGE clone cDNA 
(IMAGE id 4854519) using the following primers 
5' cgc gaa, ftc atg atg atg atg gga aag gaa aag act cat atc 
5' cgc tct aga tca ttt agc ctt ctg agc ttt ctg 39 
to introduce EcoRI and XbaI restriction sites as well as 3 extra methionine residues (to 
ensure optimal radiolabelling) into the product. After digestion the PCR product was 
cloned into the plasmid pcDNA3 (Invitrogen) downstream of the T7 promoter, and the 
presence of the insert and absence of any PCR-introduced mutations confirmed by 
restriction digest and sequencing. Plasmid DNA for subsequent use was prepared by use 
of the WizardTMmidi-prep kit (Promega) according to the manufacturer's instructions. 
4. Z2 Production of "S-methionine labelledprotein using an in vitro 
transcription1translation system. 
Linked in vitro transcription/translation was performed using the Promega Tnl7m rabbit 
reticulocyte lysate system. Approximately 4gg of plasmid DNA was used as template in 
a 200ptl reaction. A typical reaction is shown below. 
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Component Volume(gl) 
TnTlm RRL 100 
TnTTm reaction buffer 8 
TnTTm T7 RNA polymerase 4 
Amino acid mixture (minus methionine) 4 
(35S) methionine 16 
RNAsin@ ribonuclease inhibitor 40u/jil 4 
Plasmid 4 
ddH20 To 200 
The production of an appropriately sized 52kDa polypeptide was confirmed by SDS- 
PAGE in a 12% gel and autoradiography. A typical example is shown in figure 16. 
4. Z3 Immunoprecipitation (IP) assayfor anti-eEFla 
All serum samples were clarified by microcentrifugation at 130OOrpm for 15 minutes 
prior to use. Five microlitres of serum and I gl of IVTT reaction were combined with 
50gl of IP buffer (20mM Tris HCI pH8,150mM NaCl, I% triton X 100,700u/ml 
aprotinin) in 1.5ml microfuge tubes and immune complexes allowed to form by 
incubating the samples on a rotary wheel for 16 hours at 4'C. Immune complexes were 
then captured by adding 50gl of a slurry of Protein G Sepharose Fast-Flow (Amersham 
Biosciences, Bucks., UK) equilibrated in IP buffer representing 25gl of dry resin with a 
predicted binding capacity for human IgG of 425ýtg (according to manufacturer's 
infon-nation). Following incubation for lh at 4'C the Sepharose was washed 4 times with 
500gl of IP buffer for 30 minutes each time, rotating at 4T. Following the final wash the 
amount of 35 S-labelled protein bound to the Sepharose was estimated by radioscintillation 
counting using a Wallac Rackbeta beta counter. 
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Figure 16. Invitro transcription-translation of eEFla 
rn rn 
77kDa 
ommow - 5OkDa 
34kDa 
Figure 16. SDS-PAGE analysis of "S-methionine labelled eEFla synthesised by invitro trunscription-translation. One ml 
of a 200ml reaction was analysed. The positions of molecular weight markers arc shown to the right and a negative control 
reaction using empty pcDNA3 as template is also shown. 
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4. Z 4 Expression and analysis of binding data 
Because of the variability between batches of Sepharose and labelling efficiency of 
different IVTT reactions, each time the assay was performed the same 10 non-nal sera 
were tested concurrently with patient samples. Results for each sample were then 
expressed as binding units calculated according to the following fonnula: 
Binding units (sample) = cpm(sampl e) - mean cpm(I 0 controLs) 
sd (10 controls) 
It can be seen that this value corresponds to the standard non-nal variate (SNV), and a 
value of 4 representing 4 sd above the mean of the controls was selected as the cutoff for 
positivity. In this way results of assays perfonned on different occasions could be 
directly compared. 
4. Z5 Patients and sera 
Local ethics committee approval was sought and obtained. Patients with early RA have 
been described in section 2.6.6. Patients with established RA formed part of a cohort 
collected by AS Low, and Dr P Hughes provided sera from patients with SLE and 
systemic sclerosis. Polymyositis sera were kindly provided by Dr P Plotz, NIH, 
Bethesda. Graves' sera were provided by Prof AP Weetman. Sem from healthy blood 
donors were obtained from the Sheffield Blood Transfusion Service with the kind co- 
operation of Dr Virge James. 
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4. Z6 HLA -DR typing 
HLA-DR typing was performed by PCR amplification using sequence-specific 
oligonucleotide primers. Typing was performed by AS Low. 
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4.3 Results 
4.3.1 Confirmation of anti-eEFIa reactivity in 20 early RA sera usedfor selective 
enrichment 
The radioinimunoprecipitation assay described above was applied individually to the 20 
RA sera used as a pool for the selective enrichment experiments detailed in chapter 2 and 
to 20 randomly selected sera from healthy blood donors. Results are shown in figure 17. 
Four of the 20 early RA patients were considered positive and I borderline on the basis of 
this assay. In order to ensure that the binding shown above was not due to polyreactivity, 
all sera were tested in an identical assay for binding to the T cell costimulatory ligand 
B7.2 (described in chapter 5) and no binding was demonstrated. 
90 
Figure 17. Anti-eEFla reactivity of 20 early RA sera 
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Figure 17. Each symbol represents the mean of duplicates for an individual serum sample. The horizontal line represents 
an arbitrary cutoff for positivity set at 3 sd above the mean of the control sera - assuming the samples are normally 
distributed less than 0.5% of samples would be expected to be outside this range by chance. 
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4.3.2Anti-eEFlareactvity in established RA and other systemic autoiMmune diseases 
The radioimmunoprecipitation assay was then applied to panels of sera from patients with 
established RA, SLE, systemic sclerosis (SS), polymyositis (PM) and Graves' disease 
(GD). Binding data for individual sera and frequencies of positive sera are shown in 
figure 18. In total 50 RA sera were tested and 75 sera from patients with the other 
autoimmune diseases listed above. Frequencies of positive sera in each group are shown 
below as a2x2 contingency table: 
RA sera Non-RA sera Total 
Anti-eEF 1 (x + 11 1 12 
Anti-eEF I cc - 39 74 113 
Total 50 75 125 
Chi-squared = 12.5, p<0.00 I confinning that these frequencies are unlikely to have arisen 
by chance. 
4.3.3 Titration curves ofpositive RA sera 
As an additional measure to ensure that binding seen with RA patients was accurate and 
reproducible, 3 randomly selected sera designated as positive on the first screening were 
titred for their anti-eEFIct reactivity. Binding in cpm for all 3 and one normal serum 
tested concurrently for comparison is shown in figure 19. 
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Figure 18. Anti-eEFla I reactivity in patients with autoimmune diseases 
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Figure 18. Each symbol represents the mean of duplicate measurements performed for an individual patient serum. 
Frequency of positive sera are shown below each column. 
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Figure 19. Titration of three anti-eEFla positive sera 
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Figure 19. Error bars represent 95% confidence intervals based on triplicates. 
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4.3.4 Relationship of anti-eEFI a antibody to age, sex, disease duration and HLA 
alleles 
In order to address the question of whether anti-eEF I (x reactivity defines a subgroup of 
patients with RA antibody-positive and negative patients with RA were compared with 
regard to age, disease duration, gender and carriage of HLA DR*040 1, *0 10 1 and *0301 
alleles (frequencies of other alleles were too small for any meaningful comparison). Data 
are shown in table 8. 
Table 8. Characteristics of anti-eEF1 a positive and negative RA patients 
Anfi-eUla + Anfi-eEF1 a-P 
n= 11 38 
Mean age (yrs) 63 62.8 0.96 
Mean disease duration (yrs) 12.3 13.1 0.79 
Sex 
Males 2/11 12/38 
0.38 
Females 9/11 26/38 
IILA DR allele frequencies 
DR*0401 5/22 21/76 0.65 
DR*0101 3/22 11/76 0.91 
DR*0301 4/22 4/76 0.05 
Table 8. Student's t test was used to estimate the significance of differences between mean ages and 
disease duration, and the chi-squared test used to compare the proportions of males and females in each 
group and carriage rates of DR alleles. 
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4.4 Discussion 
4.4.1 Specificity of the assayfor anti-eEFI a antibody 
In any immunological assay it is important to ensure that specific binding is being 
measured, because of the frequent occurrence of polyclonal activation of B and T cells in 
systemic autoimmune diseases. Specific antibody in a serum can be demonstrated by 
binding of the cognate antigen but not an irrelevant ligand, and by competition of binding 
with pure antigen from another source but not by irrelevant ligand. Titration experiments 
illustrate the relationship of binding with concentration and thereby demonstrate that the 
binding is due to a serum factor. In addition they provide a means of comparison 
betweensera. We were able to demonstrate that a sample of anti-eEFIcc positive sera did 
not bind a control protein, and that binding was titratable and saturable. However no 
source of purified antigen or specific antibody was available, hence competition 
experiments were not performed. These data in addition to the good concordance 
between the frequency of reactivity detected and that shown by Ditzel et al support the 
view that specific binding was observed in our sera. 
4.4.2 Anti-eEFI a as a specific markerfor rheumatoid arthritis 
Panels of sera from patients with a number of diseases characterised by systemic 
autoimmunity and varying degrees ofjoint involvement were tested, however anti- 
eEF Ia reactivity was observed in only I of 75 patients without a diagnosis of RA (SLE) 
compared to II of 49 patients with RA. These data give a diagnostic sensitivity of anti- 
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eEF Ia for RA of 22%, a specificity of 98% and positive predictive value of 92%. 
Although this is an artificial patient population and these figures cannot be directly 
applied to an outpatient population for instance, they do indicate that anti- 
eEF I (x reactivity is relatively specific for RA. Similar diagnostic sensitivity is seen for 
the group of patients with early RA, suggesting that anti-eEF I cc could be used as a 
diagnostic marker in early disease - clearly a large prospective study would be required to 
address this issue. 
The single positive non-RA serum was from a patient with SLE. It is of interest that 
eEF Ia was isolated from screening of an endothelial cell cDNA library with lupus sera 
(Frampton et al., 2000), although the frequency of anti-eEF I (x in SLE has not been 
established. It is also noteworthy that the study of Ozouki et al found an association 
between anti-eEF I cc and an anti-nuclear antibody positive subgroup of patients with 
facial atopic dermatitis. Anti-cEF I cc may therefore be detected in subgroups of patients 
with SLE. 
4.4.3 Anti-eEFla reactivity may define a subset ofpatients with rheumatoid arthritis 
Anti-eEF I cc positive and negative patients were well matched with regard to age, sex and 
disease duration and carriage of DR B1 *0401 and DR B1 *0 10 1 but carriage of DR 
B1 *0301 was significantly more frequent in anti-eEF I (x positive patients. This is 
somewhat surprising given the previously described association of this antibody with 
Felty's syndrome, a phenotype strongly associated with DR BI*0401. This finding raises 
the possibility that this antibody defines a subset of patients whose disease is associated 
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with the autoinimune Al B8 DR3 TNF2 haplotype rather than the shared epitope more 
characteristic for RA. This might reflect the peptide binding requirements of different 
MHC molcculcs or discasc proccsscs mcchanistically rclatcd to DR3- associatcd 
autoimmune diseases such as SLE. It would be important to replicate this result however 
in a larger population. 
4.4.4 Why is eEFlal an autoantigen in rheumatoid arthritis? 
Much accumulating evidence suggests that loss of tolerance to self proteins may occur as 
a result of post-translational modifications occurring during apoptosis or cellular stress 
(Utz and Anderson, 1998), such as cleavage by caspases or granzyme B (Casciola-Rosen 
et al., 1999), and reversible phosphorylation or dephosphorylation (Utz et al., 1997). 
Apoptotic blebs on the surface of neutrophils contain eEF I al as mentioned previously, 
and it is therefore possible that eEF I al is rendered immunogenic by such mechanisms. 
Antibodies however are much more frequent in patients with rheumatoid arthritis than the 
connective tissue disease sera tested, suggesting that some aspect of the tissue 
perturbation involved in joint pathology may result in loss of tolerance to eEF I cc 1. 
4.4.5 Conclusions 
Anti-cEF I (x reactivity is relatively specific for rheumatoid arthritis although not very 
sensitive, and antibodies can be detected early in the disease course. Anti-eEF I (x could 
potentially be a useful adjunctive diagnostic marker in patients withjoint symptoms. In 
addition anti-eEF Ia may define a subset of patients with a different mechanism of 
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disease. The frequency of anti-eEF I (xI in other disease states particularly SLE with 
autoimmune neutropaenia and skin disease needs to be established as it may be a valuable 
marker in these situations. Production of purified recombinant protein and establishment 
of an ELISA is currently being pursued in order to attempt to study large numbers of 
sera. 
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5 Investigation of autoantibody responses against T cell costimulatory 
molecules in rheumatoid arthritis 
5.1 Introduction 
Many transgenic experiments in mice have convincingly demonstrated that the binding of 
membrane-associated antigens to surface IgM receptors on immature B cells in the bone 
marrow leads to clonal deletion (Chen et al., 1995; Nemazee and Burki, 1989). Such a 
mechanism should ensure that effective tolerance exists to those cell-surface molecules, 
particularly on haemopoietic cells and lymphocytes, which are likely to come into close 
contact with B cells during their physiological functioning (Comall et al., 1995). The 
presence in the periphery of antibodies and by implication B cells with specificity for 
such molecules might indicate a generalised defect in B cell tolerance induction 
programmes. Such antibodies may be useful as specific markers of autoimmunity. It is 
of interest therefore that patients with SLE possess anti-lymphocyte antibodies (Osman 
and Swaak, 1994) although the specificities of these are incompletely characterised. T 
cells require a second signal for activation in addition to ligation of the TcR-CD3 
complex by MHC/peptide on antigen presenting cells. The best characterised of such 
costimulatory molecules is the CD28/B7 system. Binding of B7.1 or B7.2 on antigen 
presenting cells to CD28, which is constitutivelY expressed on T cells results in the 
necessary costimulatory signal. Activation of T cells results in expression of the 
alternative B7 ligand CTLA4. CTLA4 binds to the B7 ligands with 20-50 times higher 
affinity than CD28 and transduces a negative signal to T cells. Mice deficient in CTLA4 
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have a profound lymphoproliferative and autoimmune phenotype and therefore this 
molecule is believed to have an important role in the control of T cell activation (Tivol et 
al., 1995; Waterhouse et al., 1995). One group has investigated the frequency of 
antibodies to these molecules in patients with autoirnmune diseases and detected 
antibodies to CTLA4 in 4/49 patients with SLE, 9/48 patients with rheumatoid arthritis, 
1/32 patients with systemic sclerosis, 7/22 patients with Behqet's syndrome and 2/15 
patients with Sjogren's syndrome (Matsui et al., 1999). Antibodies to B7.2 were found in 
a much smaller number of patients and antibodies to CD28 and B7.1 in none. Of interest 
also was the finding that uveitis occurred much less frequently amongst the antibody- 
positive patients than the antibody-negative patients with Behget's syndrome, implying 
an association between antibody status and disease phenotype. It is of interest therefore 
to corroborate these findings and establish whether or not similar associations can be 
found in other diseases. 
These studies were performed using bacterially produced recombinant antigen in the 
fonn of P galactosidase fusions that were adsorbed onto solid surfaces for ELISA. 
However autoantibodies in general arise in response to native protein and so often 
recognise conformational epitopes (Blanchin et al., 2002; Guo et al., 2001) and therefore 
studies on denatured protein may underestimate their true frequency. In this work 
attempts to demonstrate antibodies to T cell costimulatory molecules using two other 
methodologies are described. Radiolabelled CTLA4 and B7.2 were synthesised by in 
vitro transcription-translation and used for immunoprecipitation studies. Additionally, in 
order to analyse reactivity to native protein attempts were made to express the 
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extracellular domain (ECD) of CTLA-4 at high levels on the surface of eukaryotic cells 
using a glycosylphosphatidylinositol (GPI) anchor. This technique has been successfully 
used to display the thyrotropin receptor extracellular domain at approximately 10 times 
higher density at the cell surface than standard methods (Da Costa and Johnstone, 1998) 
and was chosen because the high expression levels may allow the problem of non- 
specific binding of human sera to cells to be overcome (Matsui et al., 1999). 
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5.2 Materials and Methods 
S. Zl Construction of CTLA4, B7.1, B7.2 and CD28ecd expression plasmids 
Complementary DNA for CTLA-4 was obtained by RT-PCR from peripheral blood 
mononuclear cells taken from a healthy volunteer which had been stimulated for 3 days 
with Sgg/ml of concanavalin A. Complementary DNA for the remaining three molecules 
could be readily amplified from unstimulated PBMCs. Primers were designed to 
incorporate BamH I (or Kpn I in the case of CTLA4) and Xho I restriction sites into the 
PCR product to allow cloning. The plasmid pcDNA3-TSHr-gpi, which carries an insert 
corresponding to the extracellular domain of the thyrotropin receptor cloned in frame 
with a GPI anchor sequence (Coyne et al., 1993) was used as the parent vector (figures 20 
and 2 1). The final constructs were all verified by sequencing. 
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Figure 20. The sequence directing the attachment of a polypeptide to a GPI anchor 
LVPRG SIE GRGTII TAYKSEGE SAE 
FFFLLILLLLLVLV Stop 
FIgure 20. The artificial amino-acid sequence shown is that which was engineered into the parent construct and begins 
immediately following residue 412 (isoleucine) of the TSHr. The underlined sequence is a thrombin cleavage site (not 
employed in this work) and the sequence highlighted in gold is the sequence directing the attachment to the GPI anchor. 
The serine residue highlighted in red represents the putative covalent attachment site of the anchor. 
104 
Figure 21. Construction of the plasmid peDNA3-CTLA4-ecd 
Leader sequence 
38aa 
NH2 
Transmembrane 
helix 
25aa 
COOH 
Extracellular domain Cytoplasmic domain 
(Ig superfamil 37aa 
123aa 
I 
Domain structure of CTLA-4 
(223aa, 24.6kDa) 
GPI anchor sequence 
Extracellular domain 
covalently attached to plasma 
membrane via GPI anchor 
Figure 21. Construction ol'thc CTLA4ecd expression plasmid is illustrated, all 4 molecules were cloned using the same 
system. 
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S. Z2 Production of 35S-labelled CTLA-4 and B 7.2 by in vitro transcription- 
translation, and immunoprecipitation assays 
The plasmids constructed above were used as templates for in vitro transcription- 
translation (IVTT) as described previously, however a polypeptide product was obtained 
only from the B7.2 construct (figure 22). In further attempts to express CTLA4, B7.2 
and CD28 an altemative method was used. Full-length cDNA was amplified using a 
sense oligonucleotide primer containing the T7 polymerase promoter and ribosome 
binding site. The linear PCR product was then used as template for IVTT. This approach 
was successful for CTLA4 (figure 23) but not for B7.1 or CD28, and no further attempts 
to express these molecules were made. Immunoprecipitaion assays were subsequently 
performed as described previously. 
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Figure 22. IVTT products from pcDNA3/CTLA4 ecd, B7.1 ecd, B7.2 ecd and CD28 ecd 
expression plasmids 
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Figure 23. IVTT of full-length CTLA-4 
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5.2.3 Transfection of Chinese Hamster Ovary (CHO) cells and selection of stable 
transformants 
CHO cells were gown in monolayer cultures in 6 well plates to 60-70% confluence. 
Each well was transfected with I gg of plasmid DNA, prepared using the Qiagen Maxi 
plasmid prep kit according to the manufacturer's instructions. Transfection was 
performed using Fugene 6 (Roche) according to the manufacturer's protocol. After 48 
hours the cells were removed from the well with trypsin and transferred to aI Ocm culture 
dish with complete medium (Ham's F 12 supplemented with 10% fetal calf serum, 2mM 
L-glutarnme, penicillin, streptomycin) supplemented with GeneticinC at 800gg/ml. The 
culture was continued with changes of medium every 48 hours until the majority of the 
cells had died and visible clumps had begun to form. When clumps of 30-50 cells were 
established 40 cell clumps were picked and cultured in 24 well plates until confluent. 
Clones were screened for cell surface CTLA4 ecd expression by FACS analysis. 
S. Z4 Indirect immunofluorescence and FACS analysis 
Sub-confluent cells in monolayer culture were removed from the plate using Cell 
Dissociation Medium (Sigma) and after washing in PBS were resuspended in I 00gl 
complete medium to which was added anti-CTLA4 monoclonal antibody (Clone BN 13, 
BD Pharmingen) or IgG2A isotype control (Serotec) at 2gg/ml and incubated for 30 
minutes at 4'C. After washing once in complete medium the cells were incubated with 
goat anti-mouse IgG FITC conjugate (Sigma) 5gg/ml for a further 30 minutes at 4'C and 
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washed again. One colour flow cytometric analysis was performed using a Becton 
Dickinson FACScan and proprietary software. 
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5.3 Results 
5.3.1 Recombinant CTLA-4 and B7.2 synthesisedhyIVTT are immunologically intact 
In order to ensure that the recombinant molecules produced above were suitable for use 
in immunological assays titration immunoprecipitation experiments were performed with 
commercially produced antibodies (figure 24). The antibodies used were a rabbit affinity 
purified polyclonal anti-CTLA4 IgG, (Santa Cruz Biotechnology) and goat polyclonal 
anti-B7.2 IgG (Santa Cruz Biotechnology). Specific and titratable binding was seen for 
each molecule. For subsequent assays each antibody was used as a positive control at a 
concentration of 8ng/gl at which concentration binding was reliably higher than 
background but in the expected range of positive sera. 
5.3.2 Absence of specific antibodies in RA patients to CTLA4 and B7.2 as assessed by 
immunoprecipitation assays 
Thirty RA sera and 30 control sera were tested for binding to each molecule. A 1/10 
dilution of serum in IP buffer (5gl of serum in a total volume of 50gl) was used. Binding 
data for individual sera are shown in figure 25. No specific binding to either CTLA4 or 
B7.2 was seen in any serum despite definite binding to control antibodies. 
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Figure 24. Binding of specific antibody to radiolabelled CTLA4 and B7.2 
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Figure 24. Panel (A) shows data for binding of each antibody to recombinant 35S-labelled CTLA4 and panel (B) for 
binding to recombinant 35S-labelled B7.2. In each case the other antibody was used as a negative control. 
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Figure 25. Reactivity of RA and control sera to 35S-labelled CTLA4 and B7.2 
A 
7000 
6000 
5000 
4000 
CL 
3000 
2000 
1000 
0 
B 
6000 
5000 
4000 
3000 
- ---------- ------ ........................ . .................................................................. . ... 
2000 
1000 
o 
* RA sera 
* Controls 
* Rabbit anti-CTLA4 
0 Ra sera 
x Controls 
A Goat anti-137.2 
Figure 25. Binding of individual sera to CTLA4 (panel A) and B7.2 ecd (panel B) are shown. Each serum was tested at a 
dilution of 1/10 (5RI serum in a total volume of 501AI). The dashed horizontal line represents 3sd above the mean of the 
control group in each assay. Control antibodies were used at 8ng/[d. 
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5.3.3 Development of aflow cytometry assayfor anti-CTLA4 antibodies 
In total 40 clones were screened for surface CTLA4ecd expression by flow cytometry. 
On initial screening 2 clones appeared to demonstrate cell surface expression however 
this was not confirmed subsequently. Synthesis of CTLA4 by the transfected clones was 
also analysed by Western blotting using the anti-CTLA4 monoclonal antibody BN 13 
against cell lysates, however no expression was seen, and therefore in the time available 
further attempts to develop this assay were not carried out. 
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5.4 Discussion 
5.4.1 Lack of reactivity to CTLA4 and B7.2 in immunoprecipitation assays 
In this work "S-labelled CTLA4 and B7.2 were synthesised in vitro and binding to 
specific antibodies demonstrated. Despite the production of immunologically intact 
recombinant polypeptides we were unable to corroborate the results of Matsui et al who 
demonstrated antibodies to CTLA4 using 0 galactosidase fusion proteins in 9/48 patients. 
In our study 30 RA sera were assayed and therefore approximately 5 or 6 sera would be 
expected to be positive. This may reflect a genuine difference in the populations studied 
however there are a number of other possible explanations for these divergent 
observations. 
5.4. LI Assay sensitivity. 
It is possible that the assay described above was relatively insensitive and the titres of 
antibody present were below the limit of detection. Without a direct comparison of 
assays this is very difficult to establish. From the titration experiments for CTLA4, a 
specific IgG concentration of Sng/gl did give a signal which could be reliably 
differentiated from background. Considering a value of I Ogg/gl as the average human 
serum IgG concentration, specific IgG would therefore need to comprise approximately 
0.05% of the total IgG to be detected (assuming human antibodies are of similar affinity 
to the rabbit antibody, a condition which may not be fulfilled). This figure is certainly 
comparable to the titre of other autoantibodies. In the study of Matsui et al antibodies 
were detected using ELISA at dilutions between I in 500 and I in 1000, suggesting they 
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are of relatively high titre and it is therefore surprising they were not detected in this 
assay. Some idea of sensitivity could have been gained by concomitant assay of a 
ubiquitous antibody in these patients such as antibodies to tetanus toxoid and may have 
helped to answer this question. 
5.4.1.2 Nature ofthe antigenic determinants. 
Immunoprecipitation assays rely on the formation of multivalent immune complexes and 
therefore require a polyclonal serum. It is well established that individual monoclonal 
antibodies often do not immmunoprecipitate their cognate antigen for this reason 
although "cocktails" often do. It is therefore possible that anti-CTLA4 antibodies 
because of their fine specificities or other properties do not efficiently form immune 
complexes in solution. Epitope mapping studies performed in the report of Matsui et al 
suggest that multiple regions of the CTLA4 molecule are recognised, however these 
studies were all performed on denatured polypeptides using ELISA and it is possible 
therefore that predominantly linear or even denatured epitopes were demonstrated, which 
may be different from those required for efficient immunoprecipitation. 
5.4.1.3 Presence ofa soluble inhibitor of binding. 
A soluble form of CTLA4 (sCTLA4) lacking the transmernbrane and cytoplasmic 
domains has been described (Magistrelli et al., 1999; Oaks et al., 2000) and can be 
detected in normal sera at concentrations ranging from 5 to I OOng/mI. A contrasting 
report suggests that levels of sCTLA4 in normal individuals is low or undetectable, and 
found elevated levels of up to I OOng/mI in patients with autoimmune thyroid disease 
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(Oaks and Hallett, 2000). This form of CTLA4 is synthesised by resting T cells and 
therefore a role as a paracrine negative regulator of T cell activation has been suggested. 
To date levels of sCTLA4 have not been assessed in other autoimmune diseases. It is a 
theoretical possibility therefore that sCTLA4 in sera may have interfered in the 
immunoprecipitation assay, although it is not clear whether sCTLA4 at up to I OOng/ml 
serum concentration (and therefore a ten-fold lesser concentration in the assay) would 
have this effect. Attempts were made to measure sCTLA4 levels in our sera. Both 
studies described above used home-made capture ELISAs with monoclonal antibody 
pairs; in each case the same monoclonal was used as capture antibody (BN13, BD 
Pharmingen) however neither of the other antibody was available and therefore the 
polyclonal rabbit IgG (Santa Cruz SC9094) was used as a secondary antibody, followed 
by a goat anti-rabbit IgG-alkaline phosphatase conjugate as detection reagent. Although 
an adequate standard curve was obtained using this system (figure 18), background levels 
with serum samples were too high for quantitation. Therefore in the absence of more 
specific reagents no further attempts to measure sCTLA4 levels were made in the current 
work. Clearly in addition the presence of autoantibodies in sera may also interfere with 
the measurement of sCTLA4 levels in ELISAs, and it is possible that this may account 
for the some of the variability in sCTLA4 levels measured in the reports above. Further 
attempts to search for antibodies to CTLA4 using these methods may therefore require 
the use of purified IgG from patients. 
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Figure 26. Standard curve of sCTLA4 ELISA 
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Figure 26. Recombinant human CTLA4-Ig fusion protein (rhuCTLA4-1g, R&D Systems) was used as standard. 
5.4.2 Conclusions 
Using radiolmmunoprecipitation assays we were unable to demonstrate the antibodies to CTLA4 
reported by another group of workers. Possible reasons for this are discussed. The importance of T 
cell costimulatory molecules in lymphocyte regulation is undisputed, and CTLA4-Ig fusion proteins are 
effective therapies for many animal models of disease. Clinical trials of CTLA4-Ig fusions in human 
disease, particularly SLE are underway. Clearly the presence of antibodies may therefore have clinical 
impact as well as providing information on diagnosis or pathogenesis. For these reasons we suggest 
that further studies are required in order to establish the frequency of anti-CTLA4 antibodies in 
systemic autoimmune diseases. 
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6 Discussion 
This thesis describes the construction of a cDNA library from rheumatoid pannus, its 
expression in both a lambda and a phage display vector, and the development of 
strategies for screening of phage displayed libraries using rheumatoid sera. The validity 
of our approach was demonstrated by the successful enrichment of a clone encoding 
eEF I (x , shown by others and ourselves to be a target of autoantibodies in patients with 
rheumatoid arthritis. 
A large body of work over the last twenty years utilising many different approaches has 
sought to characterise novel targets of antibodies in rheumatoid arthritis. Autoantibodies 
such as rheumatoid factors, anti-CCP antibodies and anti-RA33 have been demonstrated 
by a number of techniques and their presence and frequency corroborated by the work of 
independent groups. Numerous single reports of autoantibodies also exist however many 
of these remain uncorroborated, such as the anti-CTLA4 antibodies that are the subject of 
chapter 5. What therefore is the value of using another approach to search for yet more 
antibodies in rheumatoid arthritis? In contrast to the majority of previous work, we have 
focussed on patients with early disease defined as within 3 months of onset of symptoms, 
on the premise that the profile of autoantibodies present early in the disease course may 
reflect earlier pathological events. Little information exists on the frequency of 
autoantibodies at such an early point in the disease course. Many studies have reported 
the presence of autoantibodies in patients with synovitis of recent onset (Goldbach- 
Mansky et al., 2000; Kroot et al., 2000) however all included patients with onset of 
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synovitis in the previous 12 months. In addition the methodology employed in our 
studies should allow the selection of targets of autoantibodies based on binding to non- 
denatured polypeptide, and is less dependent on the abundance of individual proteins in 
target tissue, both important differences from the majority of previous work in this field. 
It is important to note that other than eEF I cc I we did not isolate any other known 
antigens of which there are several. This is fikelY to reflect the constraints of the methods 
used in terms of expression of eukaryotic sequences in a prokaryotic system and folding 
of polypeptides as well as the methods for generating cDNA. Alternative methods that 
would attempt to overcome some of these constraints might include affinity 
chromatography on IgG columns generated from patient sera and identification of 
interacting polypeptides by mass spectrometry, or indeed cloning in a eukaryotic system. 
To what extent are autoantibodies in patients with rheumatoid arthritis pathogenic, or do 
they occur as a consequence of pathologic events? Although the biological plausibility of 
antibody-mediated joint pathology is beyond doubt, little evidence for a causative role for 
antibodies in human disease exists, which would require the demonstrate of a highly 
specific autoantibody association with the disease as well as its ability to cause disease in 
adoptive transfer. To date only anti-CCP antibodies appear to be highly specific for 
rheumatoid arthritis, however no data exists on their pathogenicity in experimental 
models. Conflicting reports exist of antibodies in patients with rheumatoid arthritis to 
glucosc-6-phosphate isomcrasc as found in the K/BxN transgenic model. Fundamentally 
the presence of autoantibodies must reflect the T/B cell interaction believed to be 
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important particularly in the early stages of the disease (Cope, 2002). There is evidence 
from the study of connective tissue diseases that the development of individual antibody 
specificities is influenced by a number of biological variables including MHC restriction 
(Wilson et al., 1994), pathways for post-translational modification and degradation of 
proteins (Casciola-Rosen et al., 1999) as well as clearance of apoptotic debris from cells 
and it is likely that similar variables influence the production of specific autoantibodies in 
individuals with rheumatoid arthritis. The dissection of such influences in patients with 
rheumatoid arthritis, as initiated in chapter 4 may provide valuable data regarding 
etiology and pathogenesis of rheumatoid arthritis. 
Rheumatoid arthritis is a heterogeneous condition; hence a single characteristic 
autoantibody profile may not be expected. Because of the ease of measuring antibodies 
in blood and stWies of other systemic diseases such as vasculitis and the connective 
tissue diseases, much interest remains in the ability of autoantibodies to define clinically 
relevant subgroups of patients. However the majority of the autoantibodies described in 
rheumatoid arthritis are present in less than 50% of individuals, and do not appear to have 
any prognostic value over and above traditional assessments such as CRP and 
tender/swollen joint counts. One study has suggested that although anti-CCP positive 
patients develop rather more radiologic damage than anti-CCP negative patients, the 
predictive value of anti-CCP positivity for radiologic damage at 6 years was moderate in 
multiple regression analyses and certainly much less than that for IgM rheumatoid factor 
(Kroot et al., 2000). Anti-eEF I cc I is present in the majority of patients with Felty's 
syndrome, and data presented in chapter 4 suggests that this is not simply a reflection of 
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MHC restriction. Further work is required to test the hypothesis that these patients 
represent a clinically or pathologically distinct subgroup. 
It has been recently been shown that anti-CCP antibodies predate the onset of rheumatoid 
arthritis by several years in some cases (Dahlqvist et al., 2002; Nielen et al., 2002) 
suggesting that the pathological events relevant to the formation of autoantibodies occur 
months or years before the onset of symptoms. Recent studies on the properties of T 
cells in patients with rheumatoid arthritis suggests the possibility of an early antigen- 
driven phase of T cell activation followed by a later phase in established disease dictated 
by cytokines (Cope, 2002). Detection of disease-associated autoantibodies might 
therefore allow the identification of asymptornatic individuals in whom the study of these 
earliest events may be possible. 
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